424(b)3
File No. 333-109868

L.A.M. PHARMACEUTICAL, CORP.

Common Stock
17,653,001 Shares

By means of this prospectus a number of shareholders of L.A.M.
Pharmaceutical Corp. are offering to sell up to 17,653,001 shares of common
stock which they own or which they may at a later date acquire upon the
exercise of warrants.

L.A.M. will not receive any proceeds from the sale of the common stock by
the selling stockholders. L.A.M. will pay for the expenses of this offering.

Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the
accuracy or adequacy of this prospectus. Any representation to the contrary is a
criminal offense.

These securities are speculative and involve a high degree of risk. For a
description of certain important factors that should be considered by
prospective investors, see "Risk Factors" beginning on page 4 of this prospectus

L.A.M.'s common stock is quoted on the OTC Bulletin Board under the symbol
"LAMP." On November 25, 2003 the closing bid price for one share of the L.A.M.'s
common stock was $0.20.

The date of this prospectus is November 25, 2003

PROSPECTUS SUMMARY

L.A.M, Pharmaceutical, Corp. was incorporated in Delaware in July 1998. In
September 1998, L.A.M. acquired all of the issued and outstanding shares of LAM
Pharmaceuticals LLC ("LAM") for 6,000,000 shares of L.A.M.'s common stock. LAM
Pharmaceuticals LLC was organized in Florida in 1994 (initially as a
partnership) to commercialize a new drug delivery system which offers patients,
among other benefits, safer and more effective treatment for a number of serious
diseases. Unless otherwise indicated, all references to L.A.M. include LAM
Pharmaceuticals LLC.

L.A.M. is the owner of a proprietary wound healing and transdermal drug
delivery technology that involves the use of an original Ionic Polymer Matrix
(L.A.M. IPM(TM)) for the purpose of delivering, enhancing and sustaining the
action of certain established therapeutic agents.

The L.A.M. IPM(TM) technology combines in a matrix, in a novel manner,
those drugs that are well established and generally regarded by the public, the
regulatory authorities and pharmaceutical industry as safe. When combined with
the active drug ingredient, the L.A.M. Ionic Polymer Matrix(TM) technology
allows the delivery of greater amounts of drug to the target area than is
otherwise possible. The L.A.M. Ionic Polymer Matrix(TM) technology therefore
offers potential benefits by providing faster and more prolonged therapeutic
activity, less intrusive and less painful methods of delivery and a faster onset
of therapeutic activity.

L.A.M.'s corporate objective is to develop, market and license wound
healing and transdermally delivered drugs, both prescription and
over-the-counter, using the patented L.A.M. Ionic Polymer Matrix(TM) technology.
L.A.M. intends to seek out corporate alliances and co-marketing partnerships
where other drugs and topical products can be enhanced by L.A.M. IPM(TM)
technology.

In April 2002, L.A.M. obtained clearance from the U.S. Food and Drug
Administration ("FDA") of its Section 510(k) pre-market notification of intent
(number K020325) to market its proprietary L.A.M. IPM Wound Gel(TM). Commercial
sales of this product began in August 2002.

All of L.A.M's other products are in various stages of development and
testing, and L.A.M. has not obtained FDA approval for any of these other
products. As a result, to date L.A.M. has not generated any significant revenues
from the sale of pharmaceutical products, and expects to incur losses until
significant revenues are earned from the sale of L.A.M. IPM Wound Gel(TM) or
other products.

L.A.M.'s Head Office and Laboratory is located at 755 Center Street,
Lewiston, New York. L.A.M.'s telephone number is (877) 526-7717 and its fax
number is (716) 754-2043.

The Offering

By means of this prospectus a number of shareholders of L.A.M. are
offering to sell up to 17,653,001 shares of common stock which they own or which
they may at a later date acquire upon the exercise of options or warrants. In
this prospectus L.A.M. refers to these persons as the selling shareholders.

As of October 31, 2003, L.A.M. had 41,794,895 shares of common stock
issued and outstanding, which includes shares offered by this prospectus. The
number of outstanding shares does not give effect to shares which may be issued
pursuant to the exercise and/or conversion of options, warrants and convertible
notes previously issued by L.A.M. See "Comparative Share Data".

L.A.M. will not receive any proceeds from the sale of the shares by the
selling shareholders.

The purchase of the securities offered by this prospectus involves a high
degree of risk. Risk factors include the lack of revenues and history of loss,
and the need for additional capital. See the "Risk Factors" section of this
prospectus for additional Risk Factors.

OTC Bulletin Board Symbol: LAMP

Summary Financial Data

The financial data presented below should be read in conjunction with the
more detailed financial statements and related notes which are included
elsewhere in this prospectus along with the section entitled "Management's
Discussion and Analysis and Plan of Operations."

Results of Operations:

Income Statement Data: Nine Months
Ended Year Ended Year Ended
September 30, 2003 December 31, 2002 December 31, 2001
------------------ ----------------- -----------------

Sales $ 79,784 $ 40,160 $ --
Licensing Revenue -- -- 300,000
Operating Expenses (1,005,072) (3,530,273) (2,060,480)
Financial Accounting
Expenses (314,720) (2,809,104) (6,683,492)
Provision for Arbitration
Settlement (606,132) -- --
Interest Income -- -- 45,212
------------------ ----------------- --------------
Net Loss $(1,846,140) $(6,299,217) $(8,398,760)
============ ============ ============

Balance Sheet Data:
September 30, 2003 December 31, 2002 December 31, 2001
------------------ ----------------- -----------------

Current Assets $ 666,714 $ 780,628 $158,811
Total Assets 1,376,917 1,452,217 769,318
Current Liabilities 1,699,887 1,537,164 601,999
Total Liabilities 2,056,792 1,908,561 1,657,396
Working Capital (Deficiency) (1,033,173) (756,536) (443,188)
Stockholders' Equity (Deficit) (679,875) (456,344) (888,078)

Forward Looking Statements

This prospectus contains various forward-looking statements that are based
on L.A.M.'s beliefs as well as assumptions made by and information currently
available to L.A.M. When used in this prospectus, the words "believe", "expect",
"anticipate", "estimate" and similar expressions are intended to identify
forward-looking statements. Such statements may include statements regarding
seeking business opportunities, payment of operating expenses, and the like, and
are subject to certain risks, uncertainties and assumptions which could cause
actual results to differ materially from projections or estimates. Factors,
which could cause actual results to differ materially, are discussed at length
under the heading "Risk Factors". Should one or more of the enumerated risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated, estimated or
projected. Investors should not place undue reliance on forward-looking
statements, all of which speak only as of the date made.

RISK FACTORS

The securities being offered hereby are highly speculative and prospective
investors should consider, among others, the following factors related to the
business, operations and financial position of L.A.M.

Although L.A.M received clearance for L.A.M. IPM Wound Gel(TM) in April
2002, there is no guarantee that L.A.M. will receive regulatory approval for its
other products. Failure to obtain regulatory approvals for its other products
will prevent L.A.M. from marketing them and may significantly and adversely
affect its future financial performance. The pre-clinical and clinical testing,
manufacturing, and marketing of L.A.M.'s drug delivery systems is subject to
extensive regulation by numerous governmental authorities in the United States
and in other countries, including, but not limited to, the United States Food
and Drug Administration. Among other requirements, FDA approval, including a
review of the manufacturing processes and facilities used to produce drug
delivery products, is required before these products may be marketed in the
United States. Similarly, marketing approval by a foreign governmental authority
is typically required before L.A.M.'s drug delivery systems may be marketed in a
particular foreign country.

With the exception of L.A.M. IPM Wound Gel(TM), L.A.M.'s other products
have not been cleared by the FDA or any foreign authority. L.A.M does not expect

to be profitable until significant revenues are generated from sales of L.A.M.
IPM Wound Gel(TM), or unless and until its drug delivery products now under
development receive any required FDA or foreign regulatory clearance and are
commercialized successfully. In order to obtain FDA clearance of a product
L.A.M. must demonstrate to the satisfaction of the FDA that the product is safe
and effective for its intended uses and that L.A.M. is capable of manufacturing
the product with procedures that conform to the FDA's regulations, which must be
followed at all times. The process of obtaining FDA clearance can be costly,
time consuming, and subject to unanticipated delay. There can be no assurance
that any future clearances will be granted to L.A.M. on a timely basis, or at
all.

In addition to delays in review and approval of pre-clinical and clinical
testing, delays or rejection may also be encountered based upon changes in
applicable law or regulatory policy during the period of product development and
FDA regulatory review. Any failure to obtain, or any delay in obtaining FDA
approvals would adversely affect the ability of L.A.M. to market its other
products. Moreover, even if FDA approval is granted, any approval may include
significant limitations on indicated uses for which a product could be marketed.

Both before and after approval is obtained, a product and its manufacturer
are subject to comprehensive regulatory oversight. Violations of regulatory
requirements at any stage, including the pre-clinical and clinical testing
process, the approval process, or thereafter (including after approval), may
result in adverse consequences, including the FDA's delay in approving or
refusal to approve a product, withdrawal of an approved product from the market,
and/or the imposition of criminal penalties against the manufacturer. In
addition, later discovery of previously unknown problems relating to a marketed
product may result in restrictions on such product or manufacturer including
withdrawal of the product from the market. Also, new government requirements may
be established that could delay or prevent regulatory approval of L.A.M.'s
products under development.

If sales of L.A.M. IPM Wound Gel(TM) do not meet expectations, or cost
estimates for clinical trials and research of L.A.M.'s other products are
inaccurate, L.A.M. will require additional funding. L.A.M.'s estimates of the
future sales of L.A.M. IPM Wound Gel(TM) may be substantially higher than the
actual revenues from this product, and its estimates of the costs associated
with future clinical trials and research may each be substantially lower than
the actual costs of these activities. If L.A.M.'s revenue or cost estimates are
incorrect, L.A.M. will need additional funding for its research efforts.

There can be no assurance that L.A.M. will achieve or maintain a competitive
position or that other technological developments will not cause L.A.M.'s
proprietary technologies to become uneconomical or obsolete. The biomedical
field in which L.A.M. is involved is undergoing rapid and significant
technological change. The successful development of therapeutic agents and
products will depend on L.A.M.'s ability to be in the technological forefront of
this field. There can be no assurance that L.A.M. will achieve or maintain a
competitive position or that other technological developments will not cause
L.A.M.'s proprietary technologies to become uneconomical or obsolete.

L.A.M.'s patents might not protect L.A.M.'s technology from competitors.
Certain aspects of L.A.M.'s technologies are covered by U.S. patents. In
addition, L.A.M. has a number of patent applications pending. There is no
assurance that the applications still pending or which may be filed in the
future will result in the issuance of any patents. Furthermore, there is no
assurance as to the breadth and degree of protection any issued patents might
afford L.A.M. Disputes may arise between L.A.M. and others as to the scope,
validity and ownership rights of these or other patents. Any defense of the
patents could prove costly and time consuming and there can be no assurance that
L.A.M. will be in a position, or will deem it advisable, to carry on such a
defense. Other private and public concerns may have filed applications for, or
may have been issued, patents and are expected to obtain additional patents and
other proprietary rights to technology potentially useful or necessary to L.A.M.
The scope and validity of such patents, if any, are presently unknown. Also, as
far as L.A.M. relies upon unpatented proprietary technology, there is no
assurance that others may not acquire or independently develop the same or
similar technology.

L.A.M. has a history of losses and may never be profitable. L.A.M. has
never earned a profit. As of September 30, 2003 L.A.M.'s accumulated deficit was
approximately $(26,400,000). L.A.M. expects to incur additional losses during
the forseeable future. No assurance can be given that the launch of L.A.M. IPM
Wound Gel(TM) will be successful, or that L.A.M.'s other product development
efforts will be completed, that regulatory approvals will be obtained, that they
will be manufactured and marketed successfully, or that L.A.M. will ever earn a
profit.

If L.A.M. cannot obtain additional capital, L.A.M. may have to delay or
postpone development and research expenditures which may influence L.A.M.'s
ability to produce a timely and competitive product.

This offering is being made on behalf of certain selling shareholders.
L.A.M. will not receive any proceeds from the sale of the shares offered by the
selling shareholders. Clinical and other studies necessary to obtain approval of
a new drug can be time consuming and costly. The different steps necessary to
obtain regulatory approval, especially that of the FDA, involve significant
costs. Accordingly, L.A.M. will need additional capital in order to fund the
costs of future clinical trials, related research, and general and
administrative expenses. L.A.M. may be forced to delay or postpone development
and research expenditures if L.A.M. is unable to secure adequate sources of
funds. These delays in development would have an adverse effect on L.A.M.'s
ability to produce timely and competitive products. There can be no assurance
that L.A.M. will be able to obtain the funding which it will require.

L.A.M. may sell shares of its common stock in the future and these sales may
dilute the interests of other security holders and depress the price of L.A.M.'s
common stock.

As of October 31, 2003, L.A.M had 41,794,895 outstanding shares of common
stock, which includes shares offered by this prospectus. As of October 31, 2003,
there were outstanding options, warrants and convertible notes which would allow
the holders of these securities to purchase approximately 22,800,000 additional
shares of L.A.M.'s common stock, which includes the shares offered by this

prospectus. L.A.M. may also issue additional shares for various reasons and may
grant additional stock options to its employees, officers, directors and third
parties. See " Comparative Share Data".

The issuance or even the potential issuance of shares upon the exercise of
warrants or options, or upon the conversion of promissory notes, or in
connection with any other financing will have a dilutive impact on L.A.M.'s
other stockholders and could have a negative effect on the market price of
L.A.M.'s common stock.

As L.A.M. issues shares of its common stock as a result of the exercise of
options or warrants or upon the conversion of promissory notes, the price of
L.A.M.'s common stock may decrease due to the additional shares in the market.
Any decline in the price of L.A.M.'s common stock may encourage short sales,
which could place further downward pressure on the price of L.A.M.'s common
stock.

There is, at present, only a limited market for L.A.M.'s common stock and there
is no assurance that this market will continue.

L.A.M.'s common stock is traded on the OTC Bulletin Board. Trades of
L.A.M.'s common stock are subject to Rule 15g-9 of the Securities and Exchange
Commission, which rule imposes certain requirements on broker/dealers who sell
securities subject to the rule to persons other than established customers and
accredited investors. For transactions covered by the rule, brokers/dealers must
make a special suitability determination for purchasers of the securities and
receive the purchaser's written agreement to the transaction prior to sale. The
Securities and Exchange Commission also has rules that regulate broker/dealer
practices in connection with transactions in "penny stocks". Penny stocks
generally are equity securities with a price of less than $5.00 (other than
securities registered on certain national securities exchanges or quoted on the
NASDAQ system, provided that current price and volume information with respect
to transactions in that security is provided by the exchange or system). The
penny stock rules require a broker/ dealer, prior to a transaction in a penny
stock not otherwise exempt from the rules, to deliver a standardized risk
disclosure document prepared by the Commission that provides information about
penny stocks and the nature and level of risks in the penny stock market. The
broker/dealer also must provide the customer with current bid and offer
quotations for the penny stock, the compensation of the broker/dealer and its
salesperson in the transaction, and monthly account statements showing the
market value of each penny stock held in the customer's account. The bid and
offer quotations, and the broker/dealer and salesperson compensation
information, must be given to the customer orally or in writing prior to
effecting the transaction and must be given to the customer in writing before or
with the customer's confirmation. These disclosure requirements have the effect
of reducing the level of trading activity in the secondary market for L.A.M.'s
common stock. As a result of these rules, investors may find it difficult to
sell their shares.

COMPARATIVE SHARE DATA

As of October 31, 2003, L.A.M. had 41,794,895 outstanding shares of common
stock, which includes shares offered by this prospectus. The number of shares

outstanding as of October 31, 2003 excludes shares which may be issued upon the
conversion of promissory notes or the exercise of options and warrants issued by
L.A.M.

The issuance of additional shares and the eligibility of issued shares for
resale will dilute L.A.M.'s common stock and may lower the price of L.A.M.'s
common stock. Investors in this offering will suffer immediate dilution since
the price paid for the securities offered will likely be more then the net
tangible book value of L.A.M.'s common stock. Net tangible book value is
calculated by dividing L.A.M.'s total assets, less intangible assets and
liabilities, and dividing it by the number of outstanding shares of common
stock. The actual dilution to investors in this offering will depend on the
price which they pay for the shares.

Number of Note
Shares Reference

Shares offered by this prospectus by the selling shareholders:

Shares owned or shares issuable upon the date of
this prospectus: 10,905,251 A, E

Shares issuable upon exercise of warrants: 6,747,750 A, E

A. See the section of this prospectus entitled "Selling Shareholders" for
information concerning the names of the selling shareholders and the shares and
warrants held by the selling shareholders.

Other Shares Which May Be Issued

The following table lists additional shares of L.A.M.'s common stock which
may be issued as the result of the conversion of promissory notes or the
exercise of outstanding options or warrants:
Number of Note
Shares Reference

Shares issuable upon conversion of promissory notes 920,000 B

Shares issuable upon exercise of Series A, B, C and D
warrants 3,255,271 B

Shares issuable upon exercise of options and 12,430,621 C
warrants granted to L.A.M.'s officers, directors,
employees, private investors, and financial
consultants.

Shares issuable upon the exercise of warrants which
were issued as part of the Equity Line of Credit 938,473 D

B. In November 2002, L.A.M. sold convertible notes, plus Series A, B, C and D
warrants, to a group of private investors for $700,000. The notes do not bear
interest, are unsecured and are payable on November 1, 2005. At the holder's
option the notes are convertible into shares of L.A.M.'s common stock equal in
number to the amount determined by dividing each $1,000 of note principal to be
converted by the Conversion Price. As of October 31, 2003 the Conversion Price
was $0.12.

As of October 31, 2003 notes in the principal amount of $589,600 had been
converted into 2,252,041 shares of L.A.M.'s common stock. L.A.M. would be
required to issue an additional 1,336,666 shares of common stock if all
remaining notes were converted on October 31, 2003.

If L.A.M. sells any additional shares of common stock, or any securities
convertible into common stock at a price below the then applicable Conversion
Price, the Conversion Price will be lowered to the price at which the shares
were sold or the lowest price at which the securities are convertible, as the
case may be.

If L.A.M. sells any additional shares of common stock, or any securities
convertible into common stock at a price below the then applicable exercise
price of the Series A warrants, the exercise price of the Series A warrants will
be lowered to the price at which the shares were sold or the lowest price at
which the securities are convertible, as the case may be.

Information concerning the terms of the Series A, B, C and D warrants
follows:

Series Shares Issuable Upon Exercise Exercise Price Expiration Date

A 411,522 $0.12 11/01/07
B 1,312,500 $0.80 11/01/07
C 875,000 $1.20 11/01/07
D 656,250 $1.60 11/01/07

See "Description of Securities" for more information concerning the
convertible notes and the Series A, B, C and D warrants.

C. Options and warrants are exercisable at prices between $0.35 and $4.83 per
share and expire between January 2004 and June 2011.

D. On January 24, 2001, L.A.M. entered into an equity line of credit agreement
with Hockbury Limited in order to establish a possible source of funding for the
development of L.A.M.'s technology. The equity line of credit agreement
established what is sometimes also referred to as an equity drawdown facility.

On July 22, 2002 the Company terminated the equity line of credit
agreement with Hockbury Limited. As consideration for the cancellation of the
agreement, the Company repriced the warrants held by Hockbury Limited to
purchase 482,893 shares of common stock from a price of $4.56 per share to $1.35
per share. The warrants may be exercised at any time prior to January 24, 2004.

Prior to the termination of the equity line of credit L.A.M. had received net
proceeds of $971,000 from the sale of 1,053,177 shares of common stock under the
equity line.

E. Capital Research Group, Inc. An investor relations firm formerly used by
L.A.M. filed a claim against L.A.M. with the American Arbitration Association
alleging that L.A.M. failed to pay Capital Research Group in accordance with the
terms of an agreement between the parties. In May 2003, L.A.M. learned that the
arbitrator awarded damages in the amount of approximately $600,000 to Capital
Research Group. On November 19, 2003 L.A.M. and Capital Research Group agreed to
settle all amounts owed by L.A.M. to Capital Research Group for the following:

1. 3,059,363 shares of L.A.M.'s common stock;

2. a warrant to purchase 1,000,000 shares of L.A.M.'s common stock at a
price of $0.22 per share at any time prior to March 24, 2004;

3. a warrant to purchase that number of shares, if any, of L.A.M.'s common
stock equal to 10% of the total number of shares of L.A.M.'s common stock issued
or committed to be issued (including shares underlying any securities which are
convertible into shares of L.A.M.'s common stock but excluding any shares
included in the Selling Shareholder table of this prospectus) by L.A.M. during
the 90 day period beginning with the date of this prospectus. The warrant may be
exercised at a price of $0.01 per share at any time but prior to the later to
occur of (i) March 24, 2004; or (ii) 30 days after L.A.M. notifies Capital
Research Group in writing of the issuance by L.A.M. of shares which are issuable
upon the exercise of this warrant. Although L.A.M. does not believe this warrant
will entitle Capital Research Group to acquire any additional shares of L.A.M.'s
common stock, L.A.M. has nevertheless reserved 500,000 shares for issuance with
respect to this warrant.

The shares referred to in this Note E are being offered for sale by means
of this prospectus. See "Selling Shareholders".

Substantially all of the shares issuable upon the exercise of options and
warrants, and which are referred to in Notes B, C and D, have been, or will be,
registered for public sale by means of separate registration statements which
have been, or will be, filed with the Securities and Exchange Commission.

Market for Common STOCK.

As of October 31, 2003, there were approximately 139 record owners of
L.A.M.'s common stock. L.A.M.'s common stock is traded on the OTC Bulletin Board
under the symbol "LAMP". Set forth below are the range of high and low bid
quotations for the periods indicated as reported by the OTC Bulletin Board. The
market quotations reflect interdealer prices, without retail mark-up, mark-down
or commissions and may not necessarily represent actual transactions. L.A.M.'s
common stock began trading in August 1999.

Quarter Ending High Low

9/30/99 $ 1.38 $0.60
12/31/99 $ 4.00 $0.88

3/31/00 $10.00 $4.00
6/30/00 $ 9.25 $4.75
12/31/00 $4.75 $2.62

3/31/01 $6.06 $1.72
6/30/01 $2.75 $0.75
9/30/01 $0.95 $0.58
12/31/01 $0.76 $0.51

3/31/02 $0.99 $0.46
6/30/02 $2.50 $0.69
9/30/02 $0.88 $0.45
12/31/02 $0.54 $0.27

03/31/03 $0.34 $0.19
06/30/03 $0.24 $0.08
09/30/03 $0.21 $0.14

Holders of common stock are entitled to receive dividends as may be
declared by the Board of Directors and, in the event of liquidation, to share
pro rata in any distribution of L.A.M.'s assets after payment of liabilities.
The Board of Directors is not obligated to declare a dividend. L.A.M. has not
paid any dividends does not have any current plans to pay any dividends.

Management's discussion and Analysis
AND plan of operation

The following sets forth certain financial data with respect to L.A.M. and
is qualified in its entirety by reference to the more detailed financial
statements and notes included elsewhere in this prospectus.

Summary Financial Data

With the exception of its L.A.M. IPM Wound Gel(TM), all of L.A.M.'s
products are in the development stage. As of September 30, 2003 L.A.M. has
generated only limited revenues from the sale of its L.A.M. IPM Wound Gel(TM).

Results of Operations:

Income Statement Data: Nine Months
Ended Year Ended Year Ended
September 30, 2003 December 31, 2002 December 31, 2001
------------------ ----------------- -----------------

Sales $ 79,784 $ 40,160 $ --
Licensing Revenue -- -- 300,000
Operating Expenses (1,005,072) (3,530,273) (2,060,480)
Financial Accounting Expenses (314,720) (2,809,104) (6,683,492)
Provision for Arbitration
Settlement (606,132) -- --
Interest Income -- -- 45,212
---------------- ----------------- --------------
Net Loss $(1,846,140) $(6,299,217) $(8,398,760)
============ ============ ============

Balance Sheet Data:
September 30, 2003 December 31, 2002 December 31, 2001
------------------ ----------------- -----------------

Results of Operations

Nine months ended September 30, 2003 compared with nine months ended
September 30, 2002

Net Sales

Revenue during the nine months ended September 30, 2003 was $80,000 compared to
$22,000 recorded in the nine months ended September 30, 2002. The change is due
to the new product sales from the limited commercial introduction of L.A.M. IPM
Wound Gel(TM) which commenced in August 2002.

Research and Development Expense

Research and development expenses for the nine months ended September 30, 2003
decreased 66% to $147,000 from $433,000 for the nine months ended September 30,
2002. The decrease is due to costs incurred in 2002 to obtain regulatory
approval, granted in April 2002, for L.A.M. IPM Wound Gel(TM) that did not recur
in 2003. Research and development expenses tend to fluctuate from period to
period depending on the status and timing of the individual projects in process.

Marketing and Business Development

Marketing and business development expenses for the nine months ended September
30, 2003 decreased 56% to $330,000 from $749,000 for the nine months ended
September 30, 2002. The decrease is due to costs incurred in 2002 for the
product launch such as product design and the initial marketing campaign that
did not recur in 2003.

General and Administrative Expenses

General and administrative expenses for the nine months ended September 30, 2003
decreased 56% to $507,000 from $1,155,000 for the nine months ended September
30, 2002. The decrease is partially due to the non-recurrence of the Investor
relations costs incurred as a result of the exceptional level of activity during
the first quarter of 2002 and a reduction in financial banking and consulting
expenses as these services are now being performed internally. In addition,
there was a reduction in executive and employee salaries due to reduced
headcount, a reduction in legal expenditures as during the nine months ended
September 30, 2002 the Company was negotiating and setting in place the
distribution and business channels needed to launch the I.P.M. Wound Gel(TM) and
a write-off of a receivable in the third quarter of 2002 which did not recur in
the nine months ended September 30, 2003.

The primary components of general and administrative expenses for the nine
months ended September 30, 2003 and 2002 were as follows:

2003 2002
---------------------------

Officers' salaries $ 50,375 $ 61,250
Employee salaries and benefits 86,041 93,596
Investor Relations 29,358 210,101
Financial banking and consulting 29,688 119,340
Legal and auditing (including SEC filings) 154,109 195,624
Insurance 36,864 87,823
Write-Off of Receivable -- 289,000
Other expenses 120,516 97,829
---------- ------------
Total $ 506,951 $1,154,563
========= ==========

Interest Expense

Interest expense for the nine months ended September 30, 2003 decreased 59% to
$7,000 from $17,000 for nine months ended September 30, 2002 following the
partial repayment of loans received from Stockholders.

Share and Option Grants

L.A.M. is required to recognize non-cash expenses which represent the deemed
fair value of grants of stock options and of stock for services, calculated in
accordance with US generally accepted accounting principles. These deemed
non-cash costs, which are accounted for by correspondingly increasing L.A.M.'s
paid in capital, totaled $257,000 for the nine months ended September 30, 2003
as compared to $2,345,000 during the nine months ended September 30, 2002. The
decrease is due to options granted to an executive in February 2002 and shares
issued to third parties for services performed in the nine months ended
September 30, 2002 that did not recur in the nine months ended September 30,
2003.

The majority of these costs were attributable to shares issued to third parties
for services performed.

Other Expenses

As previously disclosed in L.A.M.'s Form 10-KSB filed on April 1, 2003, a
hearing was held on March 26, 2003 before an arbitrator with the American
Arbitration Association relating to an alleged breach of the terms of an
agreement between L.A.M. and Capital Research Group, Inc., an investor
relations firm formerly used by L.A.M. In May 2003, L.A.M. learned that the
arbitrator awarded Capital Research Group damages in the amount of
approximately $600,000. L.A.M. accrued the entire amount plus interest, at a
rate of 2% per annum, as an expense and liability in its financial statements
for the six months ended June 30, 2003. Subsequent to the entry of the
arbitration award L.A.M. and Capital Research Group agreed to settle all
amounts owed by L.A.M. to Capital Research Group for the following:

1. 3,059,363 shares of L.A.M.'s common stock;

2. a warrant to purchase 1,000,000 shares of L.A.M.'s common stock at a
price of $0.22 per share at any time prior to March 24, 2004;

3. a warrant to purchase that number of shares, if any, of L.A.M.'s common
stock equal to 10% of the total number of shares of L.A.M.'s common stock issued
or committed to be issued (including shares underlying any securities which are
convertible into shares of L.A.M.'s common stock but excluding any shares
included in the Selling Shareholder table of this prospectus) by L.A.M. during
the 90 day period beginning with the date of this prospectus. The warrant may be
exercised at a price of $0.01 per share at any time but prior to the later to
occur of (i) March 24, 2004 the date of this prospectus; or (ii) 30 days after
L.A.M. notifies Capital Research Group in writing of the issuance by L.A.M. of
shares which are issuable upon the exercise of this warrant. Although L.A.M.
does not believe this warrant will entitle Capital Research Group to acquire any
additional shares of L.A.M.'s common stock, L.A.M. has nevertheless reserved
500,000 shares for issuance with respect to this warrant.

See Note E to the "Comparative Share Data" table.

Year Ended December 31, 2002 compared with Year Ended December 31, 2001
- -----------------------------------------------------------------------

Sales

During the year ended December 31, 2002, L.A.M. commenced commercial sales
of its L.A.M. IPM Wound Gel(TM). Revenue for the sale of the product is recorded
when the revenue is realized or realizable and earned.

Licensing Revenue

During the year ended December 31, 2001, licensing revenue of $300,000 was
received from Ixora Bio-Medical Co. Inc. ("Ixora") under the terms of their
license agreement related to L.A.M.'s sexual dysfunction products. See Item 1 of
this report for further information concerning L.A.M.'s agreement with Ixora.

Interest Expense

Interest expense for the year ended December 31, 2002 decreased 91% to
$20,000 from $233,000 for the year ended December 31, 2001 due to the conversion
of all remaining debentures during 2001.

General and Administrative Expenses

General and administrative expenses for the year ended December 31, 2002
increased 43% to $1,972,000 from $1,379,000 for the year ended December 31,
2001. The increase included costs attributable to the write off of the option
receivable as described in Note H to the financial statements; increased costs
of regulatory filings in respect of past and present options, note conversions,
share grants for services and quarterly and yearly filings as required by the
Securities and Exchange Commission; and costs attributable to the increase in
insurance costs due to the launch of the L.A.M. IPM Wound Gel (TM). The increase
was offset by the decrease in investor relations due to the non-recurrence of
the exceptional level of activity in the previous year and the decrease in costs
incurred in 2001 to arrange the equity line of credit which did not recur in
2002.

The primary components of general and administrative expenses for the
years ended December 31, 2002 and 2001 were as follows:

2002 2001
---- ----

Officers' salaries $ 74,125 $ 149,612
Employee salaries and benefits 127,787 123,113
Investor Relations 265,819 337,680
Commissions and other costs in
connection with financings 83,070 138,863
Financial Banking and Consulting 194,200 197,333
Legal and Auditing (including SEC filings) 327,945 276,415

Insurance 130,882 38,745
Write off of receivable 627,000 --
Other Expenses 141,501 117,030
------------- ------------
Total $ 1,972,329 $ 1,378,791
=========== ===========

Marketing and Business Development Expense

Marketing and business development expense for the year ended December 31,
2002 increased 383% to $975,000 from $202,000 for the year ended December 31,
2001. The increase reflects the build up of marketing management and resources
and promotional activity in preparation for the commercial sales of L.A.M. IPM
Wound Gel(TM) and the introduction of the product to markets outside of the U.S.
Research and Development Expense

Research and development expenses for the year ended December 31, 2002
increased 19% to $573,000 from $480,000 for the year ended December 31, 2001.
The increase includes the scale up in production of L.A.M. IPM Wound Gel(TM) to
commercial batch quantities.

Share and Option Grants

L.A.M. is required to recognize non-cash expenses which represent the
deemed fair value of grants of stock options and of stock for services,
calculated in accordance with US generally accepted accounting principles. These
deemed non-cash costs, which are accounted for by correspondingly increasing
L.A.M.'s paid in capital, decreased to $2,468,000 for the year ended December
31, 2002 compared with $4,266,000 for the year ended December 31, 2001. The
non-cash expenses included costs attributed to options and shares granted to
consultants and directors for services performed and in recognition of their
additional efforts now required to bring L.A.M.'s first product to market; to
options granted in connection with the related strengthening of the management
team; and to other investors for their investment support.

Conversion Premium

During the years ended December 31, 2002 and 2001, conversion premiums of
$205,000 and $1,058,000 respectively were charged to expense.

The charge in 2002 related to the sale of convertible notes during that
year, and represented the difference between the deemed fair value of L.A.M.'s
common stock and the conversion price of the convertible notes sold.

The charge in 2001 represented the deemed fair value of the enhanced terms
granted in August of that year to note holders who agreed to convert their
outstanding notes during the year.

The conversion premiums did not require the use of cash.

Warrants Issued

The expense of $56,000 for the year ended December 31, 2002 represents the
fair value of the warrants issued to the Convertible Note holders and the
placement agent in connection with the issuance of the Convertible Notes.

The expense of $1,100,000 for the year ended December 31, 2001 represents
the fair value of the warrants issued to Hockbury Limited in connection with the
equity line of credit and the warrants issued to GKN Securities as placement
agent for the equity line.

Liquidity and Sources of Capital

Nine Months Ended September 30, 2003

L.A.M.'s cash and cash equivalents as of September 30, 2003 were
approximately $60,000 compared with approximately $210,000 at December 31, 2002.
Working capital deficiency increased from approximately $(757,000) as of
December 31, 2002 to $(1,033,000) as of September 30, 2003, primarily as the
result of the accrued arbitration settlement.

L.A.M.'s operations used approximately $546,000 in cash during the nine
months ended September 30, 2003 compared to $2,574,000 used in the same period
in the prior year. During the current year, changes in L.A.M.'s working capital
balances resulted in a source of cash in the amount of $846,000 compared to a
use of cash of $17,000 in the same period in the prior year. Reduced operating
expenses and increased revenue contributed to the remainder of the change in
cash requirements for the nine months ended September 30, 2003 compared to the
same period in the prior year.

During this period L.A.M. also spent $90,000 for patents, trademarks, and
equipment purchases.

Sources of cash during the nine months ended September 30, 2003 came
principally from the exercise of stock options amounting to $25,000 and from
proceeds from stock subscriptions amounting to $400,000.

L.A.M. is currently undergoing a due diligence process with respect to a
multi-tranche financing earmarked to fund both its ongoing operations and
strategic initiatives. There can be no guarantee that L.A.M. will receive
sufficient funds to implement its business plan.

During the three months ended September 30, 2003 L.A.M. sold units of
L.A.M.'s common stock in which each unit consists of 1000 shares of L.A.M.'s
common stock plus 750 warrants. Each warrant will entitle the holder to purchase
one of L.A.M.'s common stock as follows:

o One third of warrants may be exercised at any time prior to February 28,
2005 at a price of $0.30 per share

o One third of warrants may be exercised at any time prior to August 31, 2005
at a price of $0.30 per share

o One third of warrants may be exercised at any time prior to February 28,
2006 at a price of $0.50 per share

Between July 1, 2003 and October 14, 2003 L.A.M. sold 7,341,828 shares of
its common stock, plus warrants for the purchase of an additional 5,247,750
shares for proceeds and debt reduction amounting to a total of $958,000. A total
of 4,974,828 shares, plus warrants for the purchase of 3,472,000 shares were
sold to thirty-nine investors for $673,960 in cash. An additional 2,367,000
shares, plus warrants for the purchase of 1,775,250 shares, were sold to five
persons in payment of $284,040 owed by L.A.M. to these persons.

Year Ended December 31, 2002

L.A.M.'s primary source of liquidity as of December 31, 2002 is cash and
cash equivalents of $210,000. Working capital decreased from approximately
$(443,000) as of December 31, 2001 to $(757,000) as of December 31, 2002.

L.A.M.'s operations and an increase in accounts receivable and inventory
used approximately $3,241,000 in cash during the year ended December 31, 2002.
This was offset by an increase in accounts payable and accrued expenses in the
amount of $548,000, which provided cash.

During this period L.A.M. also spent $122,000 for patents, trademarks, and
equipment purchases.

Cash required during the year ended December 31, 2002 came principally
from the exercise of stock options amounting to $1,750,000, proceeds from the
sale of shares under the equity line of credit agreement amounting to $487,000
and proceeds from the sales of Convertible Notes in the amount of $700,000.

On January 24, 2001, L.A.M. entered into an equity line of credit
agreement, or equity drawdown facility, with Hockbury Limited in order to
establish a source of funding for the development of L.A.M.'s technology. As of
July 22, 2002, L.A.M. had sold 1,053,177 shares of common stock and received
$971,000 in net proceeds under the equity line of credit agreement.

On July 22, 2002 L.A.M. terminated the equity line of credit agreement
with Hockbury Limited. As consideration for the cancellation of the agreement,
L.A.M. repriced the warrants held by Hockbury Limited to purchase 482,893 shares
of common stock from a price of $4.56 per share to $1.35 per share. This
re-pricing had no effect on the operations for the year ended December 31, 2002.
The warrants may be exercised at any time prior to January 24, 2004.

See Note H to the financial statements included as part of this report for
information concerning the settlement of receivables owed to L.A.M. by a former
officer of L.A.M.

On November 1, 2002, L.A.M. sold convertible notes, plus Series A, B, C
and D warrants, to a group of private investors for $700,000. See Note J to the
financial statements included as part of this report for information concerning
this transaction. If all Series A, B, C and D warrants were exercised the
Company would receive approximately $3,775,000.

Year Ended December 31, 2001

L.A.M.'s operations and an increase in inventories used approximately
$1,713,000 in cash during the year ended December 31, 2001. This was offset by a
decrease in notes receivable and an increase in accounts payable and accrued
expenses in the amount of $256,000, which provided cash.

During this period L.A.M. also spent $282,000 for patents, trademarks, and
equipment purchases.

Cash required during the year ended December 31, 2001 came from the use of
existing cash, the exercise of stock options amounting to $112,000 and proceeds
from the sale of shares under the Equity Line of Credit Agreement amounting to
$484,000.

Plan of Operation

During the twelve months ending September 30, 2004 L.A.M. plans to:

o Continue the ongoing process of expanding its US sales channels for
L.A.M. IPM Wound Gel(TM).

o Form strategic partnerships focused on the development and marketing of
new IPM based products and acquire revenue producing products that fit
well with L.A.M.'s business strategy.

o Ensure sustained sales ramp up through the effective targeting of the
defined wound healing markets - wound care, home care, nursing homes and
podiatry.

o Seek and identify additional market segments for L.A.M. IPM Wound Gel(TM).

o Continue to develop and commercialize new derivatives of the L.A.M. IPM
Wound Gel(TM).

o Commence commercial sales of its L.A.M. IPM Wound Gel(TM)in Mexico.

o Complete the regulatory approval process for its L.A.M. IPM Wound Gel(TM)
in China and establish initial sales channels in the region.

o Pursue and establish sales representations in other international
locations, namely other Far East countries.

o Seek a European distribution partner and commence the European regulatory
approval process for the Gel.

o Continue the development of other products based on L.A.M.'s proprietary
and patented Ionic Polymer Matrix(TM) technology, including motion
sickness, and skin care.

o Continue to seek strategic relationships with international pharmaceutical
companies that will enable L.A.M. to accelerate the commercial application
of its Ionic Polymer Matrix(TM) based technology.

During this period, L.A.M. expects that it will focus the majority of its
spending on marketing and business development, in particular in respect to its
L.A.M. IPM Wound Gel(TM). L.A.M. plans to use its existing financial resources
as well as revenue streams from the sale of its L.A.M. IPM Wound Gel(TM) to fund
some of its cash requirements during this period. In addition, cash may be
raised through public or private sales of its common stock. It should be noted
that substantial funds may be needed for more extensive research and clinical
studies before L.A.M. will be able to sell other products on a commercial basis.

L.A.M. does not have any material capital commitments. Cash requirements
in the immediate future relate to general business operations including the
marketing and sales of its IPM Wound Gel(TM), and funds, if any, that may be
required to settle the Arbitration award to the investor relations firm.

Due to the previous lack of any significant revenues, to date L.A.M. has
relied upon proceeds from the public and private sale of its common stock and
convertible debentures to meet its funding requirements. Funds raised by L.A.M.
have been expended primarily in connection with research, development, clinical
studies and administrative costs. Until significant revenues commence from the
commercial sale of its products, L.A.M. will be required to fund its operations
through the sale of securities, debt financing or other arrangements. However,
there can be no assurance that such financing will be available or be available
on favorable terms.

BUSINESS

L.A.M. Pharmaceutical, Corp. was incorporated in Delaware in July 1998. In
September 1998, L.A.M. acquired all of the issued and outstanding shares of LAM
Pharmaceuticals LLC for 6,000,000 shares of L.A.M.'s common stock. LAM
Pharmaceuticals LLC was organized in Florida in 1994 (initially as a
partnership) to commercialize a new drug delivery system which offers patients,
among other benefits, safer and more effective treatment for a number of serious
diseases. Unless otherwise indicated, all references to L.A.M. include LAM
Pharmaceuticals LLC.

L.A.M. is the owner of a proprietary wound healing and transdermal drug
delivery technology that involves the use of an original L.A.M. Ionic Polymer
Matrix technology (L.A.M. IPM(TM)) for the purpose of delivering, enhancing and
sustaining the action of certain established therapeutic agents.

On April 15, 2002, L.A.M. obtained clearance from the U.S. Food and Drug
Administration ("FDA") of its Section 510(k) pre-market notification of intent
(number K020325) to market its proprietary L.A.M. IPM Wound Gel(TM). Commercial
sales of the product began in August 2002.

In order to fully understand and appreciate the significance and
effectiveness of L.A.M.'s drug delivery technology it is important to understand
how various drug-based formulations are applied to the skin and the ways that
substances applied to the skin are absorbed by the skin and other structures of
the body.

For many years, lotions, creams, suspensions and solutions of various
natural (herbal) and therapeutic (drug) substances have been applied to the
skin. When it comes to treating pain, sexual dysfunction and other disease
states which emanate from structures of the body below the skin, topical therapy
is not effective unless the therapeutic agent can penetrate the outer layer of
the skin (stratum corneum) which acts as a protective barrier. This layer
consists of numerous dead cells and cells in transition, which collectively
forms an effective barrier to penetration of substances, such as bacteria, in
the air or in water. Thus the stratum corneum plays an important role in
protecting the body from invasion by harmful substances.

It is this same protective role which has posed a major challenge over the
years regarding devising a mechanism that can effectively penetrate the stratum
corneum for the purpose of delivering therapeutic substances to structures deep
within the body.

In 1994, L.A.M.'s scientists discovered that certain molecules called
polymers were found to possess strong electrical charges which, when combined
with other polymers of a specific electrical charge, are able to effectively
penetrate the outer layers of the skin. In addition, these molecules are able to

attach or surround other molecules such as therapeutic drug molecules and carry
them within a matrix through the outer layers of the skin into the deeper
structures below. L.A.M.'s scientists recognized that these discoveries would be
of great significance to the delivery of therapeutic agents. This phenomenon,
which is the basis for the L.A.M. Ionic Polymer Matrix(TM) (L.A.M. IPM(TM))
delivery system, is covered by fourteen U.S. patents and four foreign patents
which are owned by L.A.M.

The L.A.M. Ionic Polymer Matrix(TM) technology combines in a matrix, in a
novel manner, those drugs that are well established and generally regarded by
the public, the regulatory authorities and pharmaceutical industry as safe. When
combined with the active drug ingredient, the L.A.M. Ionic Polymer Matrix(TM)
technology allows the delivery of greater amounts of drug to the target area
than is otherwise possible. The L.A.M. Ionic Polymer Matrix(TM) technology
therefore offers potential benefits by providing faster and more prolonged
therapeutic activity, less intrusive and less painful methods of delivery and
faster onset of therapeutic activity.

L.A.M.'s products are regulated in the United States by the FDA. L.A.M's
first product, L.A.M. IPM Wound Gel(TM) falls into the hydrogel and burn
dressing group as defined by the FDA, and is therefore considered a Class I
device (pursuant to FDA ruling of November 4, 1999). Class I devices are subject
to "general controls". This is the lowest level of FDA control that focuses on
basic factors such as quality regulation.

L.A.M. is of the opinion that other products which it is developing will
be classified as cosmetics, OTC drugs, or new drugs. Products classified as
cosmetics or OTC drugs may be marketed without FDA approval. New drugs that are
not cosmetics and that are not considered an OTC drug must be approved by the
FDA prior to marketing in the United States. Before human testing can begin with
respect to a new drug in the United States preclinical studies are conducted in
laboratory animals to evaluate the potential efficacy and the safety of a
product. Human clinical studies generally involve a three-phase process. The
initial clinical evaluation, Phase I, consists of administering the product and
testing for safe and tolerable dosage levels. Phase II trials continue the
evaluation of safety and determine the appropriate dosage for the product,
identify possible side effects and risks in a larger group of subjects, and
provide preliminary indications of efficacy. Phase III trials consist of testing
for actual clinical efficacy within an expanded group of patients at
geographically dispersed test sites.

L.A.M. believes that its L.A.M. IPM(TM) technology, when used with
prescription drugs, will be regulated as an unapproved new drug and will require
approval by the FDA. Conversely, L.A.M.'s IPM technology, when used with a
cosmetic or an OTC drug, could be marketed without FDA approval.

Production scale up and manufacture of L.A.M.'s IPM Wound Gel(TM) has been
contracted to an independent FDA approved manufacturer. Sales of L.A.M.'s IPM
Wound Gel(TM) began in August 2002.

L.A.M. has developed a comprehensive marketing strategy for L.A.M. IPM
Wound Gel(TM) that covers direct sales to wound healing centers and other
specialized medical practices, Internet sales, sales through contract sales
organizations and licensing.

L.A.M. is also evaluating a limited number of IPM/drug formulations that
have shown promise during preliminary clinical investigation. L.A.M.'s preferred
course for these formulations is to negotiate licensing agreements and/or joint
ventures with larger pharmaceutical companies which have the financial resources
to fund the research and/or clinical trials necessary to complete the
development of L.A.M.'s products.

If the results of the clinical trials involving these formulations are
promising, L.A.M. may then be in a position to negotiate licenses which would
generate sufficient revenue so as to allow L.A.M. to exploit the L.A.M. IPM(TM)
technology using a variety of other drugs. It should be emphasized that a number
of risks may be associated with this approach. While preliminary results have
been promising, there is no certainty that the efficacy of the IPM/drug
formulations currently being tested will be borne out in subsequent clinical
trials. In addition, more clinical studies may be requested by a potential
licensee before it is willing to enter into an agreement.

L.A.M.'s objective is to raise sufficient capital to enable it to sustain
ongoing research, marketing and administrative overhead as well as to enable it
to undertake the work necessary to obtain FDA approval for new products, if
required, and to license the products to third parties.

The longer L.A.M. is able to fund development and the clinical trials for
its products and thereby establish their efficacy, the greater their value will
be to a potential licensee given the reduced risk of failure. Consequently, the
longer L.A.M. retains sole ownership of the products the greater will be its
bargaining position with prospective licensees and strategic alliance partners.
Indeed, the industry places incrementally larger different values on drugs as
they progress through the clinical trials required by the FDA.

L.A.M. plans to market its products in any country where a suitable market
exists and which has approved L.A.M.'s products for sale.

At the present time L.A.M. is focusing its efforts on the following
projects:

WOUND HEALING

In mid-April 2002, L.A.M.'s 510(k) Pre-Marketing Notification submission
(K020325) to the FDA for L.A.M. IPM Wound Gel(TM) was cleared. This clearance
gives the Company the ability to market L.A.M. IPM Wound Gel(TM) as a Class 1
OTC device, while also acting as a platform to enable the Company to market the
product internationally.

Diabetics often have poor circulation and are prone to the development of
severe and hard to treat ulcers in the extremities, particularly in the area of
the lower legs. L.A.M. IPM Wound Gel(TM) is designed to deliver high
concentrations of sodium Hyaluronate to an ulcer bed, providing an optimal
environment for wound healing. L.A.M. IPM Wound Gel(TM) takes full advantage of
the proprietary L.A.M. Ionic Polymer Matrix(TM) technology to saturate an ulcer
bed with the L.A.M. IPM(TM) active ingredient, hyaluronic acid, a highly
purified derivative of sodium Hyaluronate, derived from avian sources.

QST Consultations Ltd., an independent consulting firm based in Allendale,
Michigan, reported very positive results of a study using L.A.M.'s IPM Wound
Gel(TM) in the treatment of hard to heal skin ulcers. By the end of the study,
47 of the 53 ulcers (89%) reported in the study, had healed within twenty-five
weeks of applying L.A.M. IPM Wound Gel(TM). The mean time to healing was 12
weeks and the median time was 8.2 weeks.

L.A.M. contracted DPT Laboratories in San Antonio, Texas to produce an
initial commercial quantity batch of L.A.M. IPM Wound Gel(TM). L.A.M. has
commenced early marketing and education efforts to promote the use of its IPM
Wound Gel(TM) for the purposes of treating difficult to heal diabetic ulcers.

As a derivative of L.A.M. IPM Wound Gel(TM), L.A.M. is also developing a
wound healing matrix designed to be used on incisions following surgical
procedures. One of the most common post-surgical complications is the
development of scar tissue, in tissue sutured or stapled following surgery.
Adhesions often form and result in a painful condition, which sometimes requires
surgical treatment. The availability of a product which could reduce such
complications will reduce the cost of post-operative care significantly. L.A.M.
believes its wound healing matrix has potential as an effective post-operative
treatment for the prevention of adhesions and scar tissue following surgery.

SEXUAL DYSFUNCTION

L.A.M.'s Personal Female Lubricant (Sexual Dysfunction) Matrix is a highly
viscoelastic (lubricating) liquid incorporating proprietary L.A.M. IPM(TM)
technology. The matrix provides enhanced lubrication while Vitamin B3 (Niacin),
encapsulated in the technology, stimulates the tissues of the female genitalia.
Vitamin B3 has long been associated with a process known as "flushing", whereby
the blood supply in the stimulated area is increased.

The L.A.M. IPM(TM) - Personal Female Lubricant (Sexual Dysfunction) Matrix
is designed primarily to address the problems of mature women who often
experience post-menopausal problems that may inhibit their intimate
relationships. Specifically, the matrix acts to either eliminate or at least
substantially minimize post-menopausal symptoms including vaginal dryness, pain
during intercourse and absence of feeling or sensation.

L.A.M. IPM(TM) - Personal Female Lubricant (Sexual Dysfunction) Matrix is
not classified as a drug. The product uses substances which have been approved
by the regulatory authorities for many applications. Vitamin B3, for example,
forms a part of B Complex taken orally as a daily supplement by millions of
people worldwide. The phenomenon of flushing is not only harmless, but has been
declared by several regulatory authorities as beneficial. Consequently, L.A.M.
believes that FDA approvals are not required for this product. L.A.M. will
ensure, however, that the matrix is manufactured to Good Manufacturing Standards
and that the product is safe and performs to its specifications.

Licensing of Sexual Dysfunction Products

In December 1997, L.A.M. granted an exclusive worldwide license to
Ixora Bio-Medical Co. Inc. ("Ixora") for the marketing, sale and distribution
of certain of its transdermal drugs for the treatment of sexual dysfunction.
L.A.M. has received licensing payments of $500,000 from Ixora. Ixora is
required to reimburse L.A.M. for all costs of clinical studies and related
research required by the FDA or other government agencies as well as patent
procurement and maintenance costs, provided however that after January 1,
2000 Ixora is not, without its consent, obligated to reimburse L.A.M. for
costs in excess of $10,000 per quarter. L.A.M. will receive the following
royalties on sales by Ixora:

o 9% of all Net Sales of licensed products approved by the FDA and for
which the patent rights have not expired.

o 6.5% of all Net Sales of all licensed products which did not require
FDA approval and for which the patent rights have not expired.

o 4.5% of all Net Sales of all licensed products for which the patent
rights have expired or have been held to be invalid.

For purposes of the license agreement the term "Net Sales" means gross
sales less advertising/promotion expenses not exceeding 8% of gross
sales and sales taxes.

In January 1998, L.A.M. acquired a 45% interest in Ixora for $207,360. As
a result of subsequent sales by Ixora of its common stock to other persons,
L.A.M, owns 18% of Ixora's common stock.

EXTREME DRY SKIN

L.A.M.'s IPM matrix spreads easily over large areas of skin, making it
ideal for use as a cosmetic in various applications to the skin. Cosmetics are a
multi-billion dollar a year industry that do not require approval before
marketing, although cosmetics must be safe, contain appropriate cosmetic
ingredients and be labeled properly. Various uses for L.A.M.'s product include
controlling body odors, relief of dryness, and for moisturization. For example,
the IPM matrix could be used as a lubricant, to replenish moisture and general
skin conditioning, particularly because it is non-staining and non-irritating.
When used with a fragrance, it could control odor. When combined with certain
over-the-counter (OTC) drugs, L.A.M.'s IPM-drug matrix could be marketed as a
cosmetic.

Certain products marketed in the United States are considered cosmetics
and OTC drugs because they make cosmetic claims as well as therapeutic claims
and are intended to treat or prevent disease. Examples of such products include,
but are not limited to, anti-dandruff shampoos; sunscreens; make-ups,
moisturizers and skin care products that bear sunscreen, skin protectant or acne
claims; products that make breath-freshening or whitening claims;
antiperspirants that bear deodorant claims; and anti-microbial soaps. These
products must comply with the FDA requirements for both cosmetics and OTC drugs.

As a cosmeceutical, a combination of an OTC drug and a cosmetic product,
the IPM matrix can be used for a variety of topical and other uses. These
include use with certain antibiotic first aid products, antifungal drugs,
dandruff, dermatitis and psoriasis control products, external analgesics, skin
protectant-type products, such as for poison ivy and fever blisters and cold
sores, first aid antiseptics, and anorectal products. Preliminary skin care
trials have been successfully completed on approximately twenty patients in the
Redding, California area by a cutaneous surgeon and dermatologist. Since L.A.M.
is of the opinion that its skin care products will be classified as a cosmetic
or an OTC drug, these skin care trials are being conducted without FDA approval.

GOVERNMENT REGULATION

L.A.M.'s drug and cosmetic products are regulated in the United States
under the Federal Food, Drug and Cosmetic Act (FD&C Act), the Public Health
Service Act, and the laws of certain states. The FDA exercises significant
regulatory control over drugs manufactured and/or sold in the United States,
including those that are unapproved.

Federal laws such as the FD&C Act cover the testing, manufacture,
distribution, marketing, labeling, advertising (for prescription drugs), of all
new drugs. Drug registration and listing requirements also exist.

L.A.M. is of the opinion that the products being developed by L.A.M. will
be subject to one or more of the following FDA classifications:

Cosmetics

Cosmetics are generally the least regulated by the FDA compared to other
products subject to the FD&C Act. The legal distinction between cosmetics and
drugs is typically based on the intended use of the product, which is normally
discerned from its label or labeling. Cosmetic products are those intended for
"cleansing, beautifying, promoting attractiveness, or altering appearance"
whereas drugs are those intended for "diagnosis, cure, mitigation, treatment, or
prevention of disease", or that "affect the structure or any function of the
body".

A claim suggesting that a product affects the body in some "physiological"
way usually renders the product a drug - even if the effect is temporary. A
claim that the product penetrates and affects layers beneath the skin's surface
most likely would be viewed by the FDA as a drug claim. However, claims that a
product affects appearance through a "physical" effect are generally considered
cosmetic claims. The FDA's rationale for this distinction is that a claim of a
physiological effect is a claim that the product "affects" the structure or
function of the body, which is one element of the statutory definition of a
drug. A claim indicating that a product's effects are on the surface of the skin
can be a cosmetic claim.

Although cosmetics may be marketed without FDA approval, in order to be
marketed lawfully as a cosmetic, the product must be properly labeled and each
ingredient and each finished cosmetic product must be adequately substantiated
for safety prior to marketing.

Products which are not cosmetics, and which are marketed in the United
States, must either comply with specified OTC drug regulations (monographs) or
be specifically approved through the New Drug Application (NDA) or biologic
licensure process.

OTC Drugs

OTC drugs generally are defined as those drug products that can be used
safely and effectively by the general public without seeking treatment by a
physician or other health care professional. Thus, they do not require a
prescription by a health care professional and are available at retail
establishments. An OTC drug may be marketed without FDA approval if it conforms
to a particular product monograph as described below and otherwise meets the
requirements of the FD&C Act.

OTC monographs list active ingredients, their dosage levels, and uses
(claims) for which OTC drug products are considered generally recognized as safe
and effective for specific use and are not misbranded. If a particular level of
an active ingredient and claim are allowed by a monograph, then a manufacturer
may market a product containing that ingredient and bearing that claim without
specific FDA approval, subject to compliance with other requirements of the
monographs and FD&C Act, including drug registration and listing obligations.
Aspirin is a common drug allowed by a monograph.

If a drug product does not conform to a particular OTC monograph, then
typically a New Drug Application must be reviewed and approved by the FDA prior
to marketing. Unlike prescription drugs, OTC drugs must bear adequate directions
for safe and effective use and warnings against misuse.

New Drug Applications and Biologic License Applications

New drugs and products that are not cosmetics or devices and that are not
covered by an OTC monograph must be approved by the FDA prior to marketing in
the United States. Pre-clinical testing programs on animals, followed by three
phases of clinical testing on humans, are typically required by the FDA in order
to establish product safety and efficacy. L.A.M. believes that its L.A.M.
IPM(TM) technology, when used with approved or unapproved prescription drugs or
biologics, will be regulated as an unapproved new drug or unapproved biologic
and will require approval by the FDA.

It is also possible that the L.A.M. IPM(TM) technology may be regulated as
a combination drug and medical device, in which case it would be subject both to
medical device and drug regulation.

Medical device regulation is based on classification of the device into
three classes, I, II, or III. Class III medical devices are regulated much like
drugs, whereas Class I and II devices are subject to abbreviated clearance
procedures. It is also possible that the use of the L.A.M. IPM(TM) technology
with a monographed OTC drug could render the product an unapproved new drug,

which would mean that the product is subject to new drug application approval
requirements before marketing.

The FDA may choose to regulate certain uses of the L.A.M. IPM(TM)
technology as a medical device if it determines that the mechanism by which the
L.A.M. IPM(TM) technology exerts its effects meets the definitional requirements
of a medical device. A medical device is a product that, among other
requirements, does not achieve its primary intended purposes through chemical
action within or on the human body and is not dependent upon being metabolized
for the achievement of its primary intended purposes. Although L.A.M. expects
that most uses of the L.A.M. IPM(TM) technology will be regulated as a drug,
which is in essence a product that usually achieves its effects by chemical
action or physiological action in or on the body, to the extent that the L.A.M.
IPM(TM) technology is used to deliver pharmaceutically active ingredients, it
can be subject to both medical device and drug regulation.

The first stage of evaluation, pre-clinical testing, must be conducted in
animals. After safety has been demonstrated, the test results are submitted to
the FDA (or a state regulatory agency) along with a request for authorization to
conduct clinical testing, which includes the protocol that will be followed in
the initial human clinical evaluation. If the applicable regulatory authority
does not object to the proposed study, the investigator can proceed with Phase I
trials. Phase I trials consist of pharmacological studies on a relatively few
number of human subjects under rigidly controlled conditions in order to
establish lack of toxicity and a safe dosage range.

After Phase I testing is completed, one or more Phase II trials are
conducted in a limited number of patients to continue to test the product's
safety and also its efficacy, i.e. its ability to treat or prevent a specific
disease. If the results appear to warrant further studies, the data are
submitted to the applicable regulatory authority along with the protocol for a
Phase III trial. Phase III trials consist of extensive studies in large
populations designed to assess the safety of the product and the most desirable
dosage in the treatment or prevention of a specific disease. The results of the
clinical trials for a new drug are submitted to the FDA as part of a New Drug
Application ("NDA").

Biological drugs, such as vaccines, are subject to Biologics License
Applications (BLAs), not NDAs as are other drugs. They must be safe, pure and
potent. Generic competition does not exist for biologics, as it does for other
drugs. Biological drugs are generally subject to the same testing,
manufacturing, distribution, marketing, labeling, advertising and other
requirements for other drugs.

To the extent all or a portion of the manufacturing process for a product
is handled by an entity other than L.A.M., the manufacturing entity is subject
to inspections by the FDA and by other Federal, state and local agencies and
must comply with FDA Good Manufacturing Practices ("GMP") requirements. In
complying with GMP regulations, manufacturers must continue to expend time,
money and effort in the area of production, quality control and quality
assurance to ensure full compliance.

L.A.M. may undertake extensive and costly clinical testing to assess the
safety and efficacy of its potential drug delivery systems. Failure to comply
with FDA regulations applicable to such testing can result in delay, suspension
or cancellation of testing, and refusal by the FDA to accept the results of the
testing. In addition, the FDA may suspend clinical studies at any time if it
concludes that the subjects or patients participating in trials are being
exposed to unacceptable health risks. Further there can be no assurance that
human clinical testing will show any of L.A.M.'s drug delivery systems to be
safe and effective or that data derived from any testing will be suitable for
submission to the FDA.

The processes required by European regulatory authorities before L.A.M.'s
systems can be marketed in Western Europe are similar to those in the United
States. First, appropriate pre-clinical laboratory and animal tests must be
done, followed by submission of a clinical trial exemption or similar
documentation before human clinical studies can be initiated. Upon completion of
adequate and well controlled clinical studies in humans that establish that the
drug is safe and efficacious, regulatory approval of a Market Authorization
Application must be obtained from the relevant regulatory authorities. As with
the FDA review process, there are numerous risks associated with the Market
Authorization Application review. Additional data may be requested by the
regulatory agency reviewing the Market Authorization Application to demonstrate
the contribution of a product component to the clinical safety and efficacy of a
product, or to confirm the comparable performance of materials produced by a
changed manufacturing process or at a changed manufacturing site.

The process of biologic and new drug development and regulatory approval
or licensure requires substantial resources and many years. There can be no
assurance that regulatory approval will ever be obtained for products developed
by L.A.M. Authorization for testing, approval for marketing of drugs, including
biologics, by regulatory authorities of most foreign countries must also be
obtained prior to initiation of clinical studies and marketing in those
countries. The approval process varies from country to country and the time
period required in each foreign country to obtain approval may be longer or
shorter than that required for regulatory approval in the United States.

There are no assurances that clinical trials conducted in foreign
countries will be accepted by the FDA for approval in the United States. Product
approval or licensure in a foreign country does not mean that the product will
be approved or licensed by the FDA and there are no assurances that L.A.M. will
receive any approval or license by the FDA or any other governmental entity for
the marketing of a drug product. Likewise product approval by the FDA does not
mean that the product will be approved or licensed by any foreign country.

Product Status

L.A.M. has completed the development of its IPM Wound Gel(TM) and obtained
clearance (number K020325) from the FDA on April 15, 2002 to market the product.
L.A.M. began commercial sales of this product in August 2002.

All of L.A.M.'s other products are in various stages of development and
testing and the commercial sale of any of these products may not occur until
2004 at the earliest. As a result, L.A.M. expects to incur significant product

development costs for the foreseeable future. L.A.M.'s estimates of the costs
associated with future research and clinical studies may be substantially lower
than the actual costs of these activities. If L.A.M.'s cost estimates are
incorrect, L.A.M. will need additional funding for its research efforts. There
can be no assurance that L.A.M.'s other products will prove to have any
therapeutic or other value.

The following is a summary of the status of the products which are being
developed by L.A.M.:
Projected Cost Projected Date
Anticipated FDA Needed to Complete of Completion
Product Name Classification Studies/Trials of Studies/Trials
- ------------ --------------- ------------------ -----------------

Wound Healing Cosmetic/OTC Drug $1,000,000(1) Completed
Female Sexual Dysfunction Cosmetic/OTC Drug $1,500,000 Dec. 2003 (2)
Extreme Dry Skin Cosmetic/OTC Drug $1,500,000 (3)

(1) Projected costs associated with the wound healing product include costs
for scaling up production.

(2) L.A.M. has licensed this product to Ixora Bio-Medical Co. Inc. Pursuant to
the terms of the Licensing Agreement, Ixora is responsible for all the
costs required to obtain any required regulatory approval for this
product.

(3) L.A.M. plans an aggressive sampling program for its Extreme Dry Skin
product with consumers, doctors and skin care professionals once its wound
healing product becomes more established in its market.

Research and Development

As part of its ongoing research and development program, L.A.M. intends to
develop and commercialize as many products as possible based on its L.A.M.
IPM(TM) technology. L.A.M.'s long-range goal is to exploit other uses of its
matrix drug delivery system to improve the therapeutic effects of various drugs.

During the years ended December 31, 2001 and 2002 L.A.M. spent
approximately $480,000 and $573,000 respectively on research and development.
During the six months ended June 30, 2003 L.A.M. spent approximately $120,000 on
research and development. L.A.M.'s research and development expenditures do not
include research and development expenses relating to L.A.M.'s Sexual
Dysfunction Drug which were paid by Ixora Bio-Medical Co. Inc.

Patents and Trademarks

As of October 14, 2003, L.A.M. owned fourteen U.S. patents, four foreign
patents, five U.S. patent applications and numerous international patent
applications designating over 100 foreign countries with claims relating to its
sustained release delivery matrix system, systems containing drug preparations,

uses of the systems for various treatment therapies and addiction therapeutic
program.

L.A.M.'s patents will expire between 2015 and 2018.

Employees

As of October 31, 2003, L.A.M. had six full time employees and one part
time employee.

offices and facilities
- ----------------------
In the fourth quarter of 2001, L.A.M. consolidated its research, pilot
production and head office activities into its 3,500 square foot facility in
Lewiston, New York. This facility is leased at a rate of $1,700 per month. The
lease on this space expires in December 2003.

L.A.M. continues to maintain a business office at 800 Sheppard Avenue
West, Commercial Unit 1, Toronto, Ontario, Canada. L.A.M. has leased this space
at $4,675 per month until August 31, 2004.

Management

Name Age Position

Joseph T. Slechta 54 President, Chief Executive
Officer, Chief Operating Officer
and Director
Peter Rothbart, M.D. 64 Treasurer and Director
Gary M. Nath 58 Secretary and Director

Joseph T. Slechta has been L.A.M.'s Chief Operating Officer since November
2000. Mr. Slechta was appointed a director and became L.A.M.'s President on May
11, 2001. Mr. Slechta became L.A.M.'s Chief Executive Officer in November 2002.
Between November 1998 and November 2000, Mr. Slechta was a consultant to L.A.M.
Between 1994 and 2000 Mr. Slechta assisted corporate clients in financing,
reorganization, expansion and improving operations. From 1987 to 1992, Mr.
Slechta held executive management positions with three Canadian corporations.
His corporate assignments included the management and financing of a
high-technology company, the reorganization and sale of a helicopter company and
financial consulting services to a major Canadian life insurance company. From
1979 to 1986 Mr. Slechta managed the treasury operations of Continental Bank.

Peter Rothbart, M.D., Medical Director, has been a director and Treasurer
of L.A.M. since its inception. He has been a consulting anesthetist for over 20
years and is a leading pain specialist and principal of the Rothbart Pain
Management Clinic in Ontario, Canada. Dr. Rothbart is currently President of the
North American Cervicogenic Headache Society, an association of specialists in
the treatment of cervicogenic headaches. He was also recently elected Chair of
the Chronic Pain Section of the Ontario Medical Association. In collaboration
with Alan Drizen, Dr. Rothbart discovered the IPM delivery system.

Gary M. Nath has been Secretary and a director of L.A.M. since its
inception. He has a BS degree in Biology and Chemistry, two years of
post-graduate work in Biochemistry and a law degree. Mr. Nath has worked in the
patent and trademark law departments of FMC Corporation, NL Industries, and
Warner Lambert Company in the capacities of patent attorney, group patent and
trademark counsel and general patent counsel, respectively. Mr. Nath is the
founding and managing partner of the intellectual property law firm Nath &
Associates located in Washington, DC. He counsels a wide range of domestic and
international clients across a broad range of technologies, including chemical,
pharmaceutical, biotechnical and mechanical fields. He has published extensively
and has spoken on intellectual property law procurement, enforcement and
transfer before numerous professional and lay groups in the United States and
Japan. He is a member of the American Bar Association, the New Jersey Bar
Association, the American Intellectual Property Law Association, the
International Patent Association, the Association of University Technology
Managers, and is admitted to practice before the U.S. Patent and Trademark
Office, Canadian Patent Office and numerous courts around the United States.

Key Employee

Elena Milantoni (age 33) has been L.A.M.'s Director of Finance and
Administration since June 2002. Ms. Milantoni has a BAS degree in accounting
and is a Chartered Accountant. Ms. Milantoni has over 10 years experience in
public accounting and industry for both bio-tech and hi-tech companies.

Management Changes

In November 2002 Alan Drizen resigned as L.A.M.'s Chief Executive
Officer. Joseph Slechta, L.A.M.'s President, was appointed L.A.M.'s Chief
Executive Officer by the Board of Directors to fill the vacant position. Mr.
Drizen resigned as a director of L.A.M. in December 2002.

In April 2003, Rick Brokenshire resigned as L.A.M.'s Vice President of
Sales and Marketing. L.A.M. is currently outsourcing this role.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act of 1934 requires directors,
executive officers and 10% or greater shareholders of L.A.M. to file with the
Securities and Exchange Commission initial reports of ownership (Form 3) and
reports of changes in ownership of equity securities of L.A.M. (Form 4 and Form
5) and to provide copies of all such forms as filed to L.A.M. To L.A.M.'s
knowledge, the following persons did not file all reports required by Section
16(a) during the fiscal year ended December 31, 2001.

Number of
Type Number of Transactions
Name of Report Reports Not Filed Not Reported

Peter Rothbart Form 4 8 17
Alan Drizen Form 4 17 681

Executive Compensation.

The following table sets forth in summary form the compensation earned or
received by (i) the Chief Executive Officer of L.A.M. and (ii) by each other
executive officer of L.A.M. who earned or received in excess of $100,000 during
the fiscal years ended December 31, 2000, 2001 and 2002.

Annual Compensation Long Term Compensation
------------------------------- ----------------------------
Re- All
stric- Other
Other ted Com-
Name and Compen- Stock Options pensa-
Principal Fiscal Salary Bonus sation Awards Granted tion
Position Year (1) (2) (3) (4) (5) (6)
- ----------- ----- ------- ----- ------- ------ ------ ------

Joseph Slechta 2002 $102,000 -- -- -- -- --
President and 2001 $103,000 $25,000 -- $85,000 3,600,000 --
Chief Executive
Officer

Alan Drizen, 2002 $80,000 -- -- -- 2,000,000 --
(former Chief 2001 $120,000 -- -- -- 300,000 --
Executive 2000 $120,000 -- -- -- -- --
Officer)

(1) The dollar value of base salary (cash and non-cash) received or earned.
(2) The dollar value of bonus (cash and non-cash) received.
(3) Any other annual compensation not properly categorized as salary or bonus,
including perquisites and other personal benefits, securities or property.
(4) During the period covered by the foregoing table, the shares of restricted
stock issued as compensation for services. The table below shows the number
of shares of L.A.M.'s common stock owned by the officers listed above, and
the value of such shares as of December 31, 2002:

Name Shares Value

Joseph Slechta 20,000 $ 5,600

(5) The shares of common stock to be received upon the exercise of all stock
options granted during the period covered by the table
(6) All other compensation received that L.A.M. could not properly report in
any other column of the table.

The following shows the amounts which L.A.M. expects to pay to its
officers during the twelve month period ending December 31, 2003, and the time
which L.A.M.'s executive officers plan to devote to L.A.M.'s business. L.A.M.
does not have employment agreements with any of its officers.

Proposed Time to be Devoted
Name Compensation To Company's Business

Joseph Slechta $120,000 100%
Peter Rothbart -- 5%
Gary M. Nath -- 15%

L.A.M.'s Board of Directors may increase the compensation paid to
L.A.M.'s officers depending upon the results of L.A.M.'s future operations.

As explained below, Gary Nath provides legal services to L.A.M. During the
year ending December 31, 2003, L.A.M. expects that it will continue to use the
services of Mr. Nath's law firm.

Long Term Incentive Plans - Awards in Last Fiscal Year

None.

Employee Pension, Profit Sharing or Other Retirement Plans

L.A.M. does not have a defined benefit, pension plan, profit sharing or
other retirement plan, although L.A.M. may adopt one or more of such plans in
the future.

Compensation of Directors

Standard Arrangements. At present, L.A.M. does not pay its directors
for attending meetings of the Board of Directors, although L.A.M. may adopt a
director compensation policy in the future. L.A.M. has no standard
arrangement pursuant to which directors of L.A.M. are compensated for any
services provided as a director or for committee participation or special
assignments.

Other Arrangements. During the year ended December 31, 2002, and
except as disclosed elsewhere in this prospectus, no director of L.A.M.
received any form of compensation from L.A.M.

See " Stock Option and Bonus Plans" below for information concerning stock
options and stock bonuses granted to L.A.M.'s officers and directors.

Stock Option and Bonus Plans

L.A.M. has an Incentive Stock Option Plan, a Non-Qualified Stock Option
Plan and a Stock Bonus Plan. A summary description of each Plan follows. In some
cases these three Plans are collectively referred to as the "Plans".

Incentive Stock Option Plan The Incentive Stock Option Plan authorizes the
issuance of options to purchase up to 1,000,000 shares of L.A.M.'s common stock,
less the number of shares already optioned under both this Plan and the
Non-Qualified Stock Option Plan. The Incentive Stock Option Plan became
effective on March 15, 2000 and will remain in effect until March 15, 2010
unless terminated earlier by action of the Board. Only officers, directors and
key employees of L.A.M. may be granted options pursuant to the Incentive Stock
Option Plan.

In order to qualify for incentive stock option treatment under the
Internal Revenue Code, the following requirements must be complied with:

1. Options granted pursuant to the Plan must be exercised no later than:

(a) The expiration of thirty (30) days after the date on which an option
holder's employment by L.A.M. is terminated.

(b) The expiration of one year after the date on which an option holder's
employment by L.A.M. is terminated, if such termination is due to the
Employee's disability or death.

2. In the event of an option holder's death while in the employ of
L.A.M., his legatees or distributees may exercise (prior to the
option's expiration) the option as to any of the shares not
previously exercised.

3. The total fair market value of the shares of common stock (determined
at the time of the grant of the option) for which any employee may be
granted options which are first exercisable in any calendar year may
not exceed $100,000.

4. Options may not be exercised until one year following the date of
grant. Options granted to an employee then owning more than 10% of
the Common Stock of L.A.M. may not be exercisable by its terms after
five years from the date of grant.

5. The purchase price per share of common stock purchasable under an
option is determined by the Committee but cannot be less than the
fair market value of the common stock on the date of the grant of the
option (or 110% of the fair market value in the case of a person
owning L.A.M.'s stock which represents more than 10% of the total
combined voting power of all classes of stock).

Non-Qualified Stock Option Plan. The Non-Qualified Stock Option Plan
authorizes the issuance of options to purchase up to 10,000,000 shares of
L.A.M.'s common stock less the number of shares already optioned under both this
Plan and the Incentive Stock Option Plan. The Non-Qualified Stock Option Plan
became effective on March 15, 2000 and will remain in effect until March 15,
2010 unless terminated earlier by the Board of Directors. L.A.M.'s employees,
directors, officers, consultants and advisors are eligible to be granted options
pursuant to the Plan, provided however that bona fide services must be rendered
by such consultants or advisors and such services must not be in connection with
the offer or sale of securities in a capital-raising transaction. The option
exercise price is determined by the Committee but cannot be less than the market
price of L.A.M.'s Common Stock on the date the option is granted.

Options granted pursuant to the Plan not previously exercised terminate
upon the date specified when the option was granted.

Stock Bonus Plan. Up to 8,000,000 shares of common stock may be granted
under the Stock Bonus Plan. Such shares may consist, in whole or in part, of
authorized but unissued shares, or treasury shares. Under the Stock Bonus Plan,
L.A.M.'s employees, directors, officers, consultants and advisors are eligible
to receive a grant of L.A.M.'s shares; provided, however, that bona fide
services must be rendered by consultants or advisors and such services must not
be in connection with the offer or sale of securities in a capital-raising
transaction.

Other Information Regarding the Plans. The Plans are administered by
L.A.M.'s Board of Directors. The Board of Directors has the authority to
interpret the provisions of the Plans and supervise the administration of the
Plans. In addition, the Board of Directors is empowered to select those persons
to whom shares or options are to be granted, to determine the number of shares
subject to each grant of a stock bonus or an option and to determine when, and
upon what conditions, shares or options granted under the Plans will vest or
otherwise be subject to forfeiture and cancellation.

In the discretion of the Board of Directors, any option granted pursuant
to the Plans may include installment exercise terms such that the option becomes
fully exercisable in a series of cumulating portions. The Board of Directors may
also accelerate the date upon which any option (or any part of any options) is
first exercisable. Any shares issued pursuant to the Stock Bonus Plan and any
options granted pursuant to the Incentive Stock Option Plan or the Non-Qualified
Stock Option Plan will be forfeited if the "vesting" schedule established by the
Board of Directors at the time of the grant is not met. For this purpose,
vesting means the period during which the employee must remain an employee of
L.A.M. or the period of time a non-employee must provide services to L.A.M. At
the time an employee ceases working for L.A.M. (or at the time a non-employee
ceases to perform services for L.A.M.), any shares or options not fully vested
will be forfeited and cancelled. At the discretion of the Board of Directors,
payment for the shares of Common Stock underlying options may be paid through
the delivery of shares of L.A.M.'s Common Stock having an aggregate fair market
value equal to the option price, provided such shares have been owned by the
option holder for at least one year prior to such exercise. A combination of
cash and shares of Common Stock may also be permitted at the discretion of the
Board of Directors.

Options are generally non-transferable except upon death of the option
holder. Shares issued pursuant to the Stock Bonus Plan will generally not be
transferable until the person receiving the shares satisfies the vesting
requirements imposed by the Board of Directors when the shares were issued.

L.A.M.'s Board of Directors of L.A.M. may at any time, and from time to
time, amend, terminate, or suspend one or more of the Plans in any manner it
deems appropriate, provided that such amendment, termination or suspension
cannot adversely affect rights or obligations with respect to shares or options
previously granted. The Board of Directors may not, without shareholder
approval: make any amendment which would materially modify the eligibility
requirements for the Plans; increase or decrease the total number of shares of
Common Stock which may be issued pursuant to the Plans except in the case of a
reclassification of L.A.M.'s capital stock or a consolidation or merger of
L.A.M.; reduce the minimum option price per share; extend the period for
granting options; or materially increase in any other way the benefits accruing
to employees who are eligible to participate in the Plans.

The Plans are not qualified under Section 401(a) of the Internal Revenue
Code, nor are they subject to any provisions of the Employee Retirement Income
Security Act of 1974.

Summary. The following sets forth certain information as of October 31,
2003 concerning the stock options and stock bonuses granted by L.A.M. Each
option represents the right to purchase one share of L.A.M.'s common stock.

Total Shares Remaining
Shares Reserved for Shares Options/
Reserved Outstanding Issued As Shares
Name of Plan Under Plan Options Stock Bonus Under Plan

Incentive Stock Option Plan 1,000,000 -- N/A 1,000,000
Non-Qualified Stock Option
Plan 10,000,000 6,727,000 N/A 1,698,000
Stock Bonus Plan 8,000,000 N/A 6,286,672 1,713,328

Options Granted

The following tables set forth information concerning the options granted
between January 1, 2001 and October 31, 2003 to L.A.M.'s officers, directors,
employees and consultants and options exercised as of October 31, 2003.

Shares Expiration Options Expired/
Subject Exercise Date of Date of Exercised as of
Option Holder To Option Price Grant Option October 31, 2003
- ------------- --------- -------- ------- -------- --------------

Joseph T. Slechta 300,000 $0.58 04/02/01 06/05/06 --
Joseph T. Slechta 300,000 $0.58 07/16/01 06/05/06 --
Joseph T. Slechta 3,000,000 $0.58 07/16/01 06/30/11 --
Peter Rothbart, M.D. 300,000 $0.58 07/16/01 06/05/06 --
Gary M. Nath 300,000 $0.58 07/16/01 06/05/06 300,000

Alan Drizen 300,000 $0.58 07/16/01 06/05/06 300,000
Alan Drizen 2,000,000 $0.58 02/22/02 02/22/07 800,000
Other employees and
consultants 1,802,000 $0.58 various dates 2007 175,000
--------- -------------
8,302,000 1,575,000
========= =========

All options shown above were granted pursuant to L.A.M.'s Non-Qualified
Stock Option Plan. Substantially all of the shares issuable upon the exercise of
the options shown above have been registered for public sale by means of a
registration statement on Form S-8 which has been filed with the Securities and
Exchange Commission.

Option Exercises and Option Values
Number of
Securities Value of
Underlying Unexercised
Unexercised In-the-Money
Options at Options at
Shares December 31,2002 December 31,2002
Acquired on Value Exercisable/ Exercisable/
Name Exercise (1) Realized (2) Unexercisable(3) Unexercisable(4)
- ---- ------------ ---------- ---------------- -----------------

Joseph Slechta 90,000 $ 32,400 3,600,000/-- $--/--
Peter Rothbart 120,000 $ 49,500 300,000/-- $ --/--
Gary M. Nath 490,000 $ 29,400 --/-- $ --/--
Alan Drizen 2,650,000 $309,000 1,200,000/-- $ --/--

(1) The number of shares received upon exercise of any options.

(2) With respect to options exercised the dollar value of the difference
between the option exercise price and the market value of the option shares
purchased on the date of the exercise of the options.

(3) The total number of unexercised options held as of December 31, 2002,
separated between those options that were exercisable and those options
that were not exercisable.

(4) For all unexercised options held as of December 31, 2002, the excess of the
market value of the stock underlying those options as of December 31, 2002
over the option exercise price.

Other Options

During 2002 certain persons, who were not affiliated with L.A.M., assigned
options to purchase shares of L.A.M.'s common stock to the following persons:

Options
Shares Issuable Exercised
Upon Exercise Exercise Expiration as of
Name of Options Price Date October 31, 2003
---- ------------- -------- --------- ----------------

Joseph T. Slechta 190,000 $0.58 1/18/08 90,000
Peter Rothbart 190,000 $0.58 1/18/08 120,000
Gary M. Nath 190,000 $0.58 1/18/03 190,000
Alan Drizen (1) 1,550,000 $0.58 1/18/03 1,550,000

On January 10, 2003 L.A.M. issued the options described below:

Options
Shares Issuable Exercised
Upon Exercise Exercise Expiration as of
Name of Options Price Date October 31, 2003
---- ------------- -------- --------- ----------------

Alan Drizen (1) 750,000 $0.58 7/13/08 --

(1) Mr. Drizen resigned as an officer of L.A.M. in November 2002 and resigned as
a director of L.A.M. in December 2002.

Stock Bonuses

As of October 31, 2003 the following persons had been granted shares of
L.A.M.'s common stock as stock bonuses:

Shares Issued
Name as Stock Bonus Date Issued

Joseph T. Slechta 100,000 06/05/01
Independent consultants 1,346,500 04/02/02
Independent consultants 125,000 07/26/02
Independent consultants 325,000 10/07/02
Independent consultants 335,000 01/08/03
Independent consultants 2,545,000 08/12/03
Independent consultants 1,095,172 08/25/03
Independent consultants 165,000 09/09/03
Joseph Slechta 250,000 09/25/03
----------
6,286,672

Certain Relationships and Transactions.

In September 1998, L.A.M. sold shares of its common stock to the
persons, in the amounts, and for the consideration set forth below:

Number
Name of Shares Consideration

Alan Drizen 1,076,308 (1) $10,763

Peter Rothbart 1,076,308 (2) $10,763

Gary M. Nath 742,784 $7,423

In September 1998, L.A.M. issued 6,000,000 shares of its common stock in
consideration for all of the issued and outstanding shares of LAM
Pharmaceuticals LLC, a Florida limited liability company. See "Business" for
further information concerning the acquisition of LAM Pharmaceuticals LLC. The
following officers, directors and other persons received shares of L.A.M.'s
common stock in connection with this transaction.

Name Shares Acquired

Alan Drizen 1,603,616 (1)
Peter Rothbart 1,603,616 (2)
Gary M. Nath 1,105,942
Lisa Krinsky 674,510 (3)
Arnold Hantman 376,019
All Other Sellers as a Group 636,297
----------
6,000,000

(1) Includes shares held by the Canyon Trust, a discretionary trust, of which
Mr. Drizen may be deemed the beneficial owner.
(2) Includes shares held by the Shasqua Trust, of which Dr. Rothbart may be
deemed the beneficial owner.
(3) Includes shares held by the South Florida Bioavailability Clinic of which
Lisa Krinsky is the majority shareholder.

Subsequent to September 1998, Mr. Drizen, Dr. Rothbart and Mr. Nath sold a
portion of their shares in transactions which were exempt pursuant to Rule 144
of the Securities and Exchange Commission and gifted a portion of their shares
to relatives.

During 2000, 2001 and 2002 L.A.M. paid $51,262, $166,532 and $99,965
respectively to Nath & Associates, PLLC for legal services. Nath & Associates,
PLLC is a law firm in which Mr. Nath, an officer and director of L.A.M., is a
partner. As of December 31, 2002, L.A.M. owed Nath & Associates, PLLC
approximately $338,000 for legal services.

Prior to January 1, 1998, L.A.M. received advances from Mr. Drizen
($525,000), Dr. Rothbart ($170,000) and Mr. Nath ($475,000) that were used to
fund L.A.M.'s operations, research and development and clinical trials.
Subsequently additional advances were made, expenses disbursed and services
performed by these directors on behalf of L.A.M. At December 31, 2001, the total
of all such advances outstanding amounted to $848,037.

Between February 2, 2001 and April 26, 2001 Mr. Drizen, an officer and one
of three directors of L.A.M. at that time, borrowed $1,075,000 from L.A.M. The
amounts borrowed by Mr. Drizen were used to purchase 441,200 shares of L.A.M.'s
common stock between February 2, 2001 and May 10, 2001 in an effort to stabilize
L.A.M.'s stock price in the face of extensive short selling. Dr. Peter Rothbart,
also an officer and director of L.A.M., was advised by Mr. Drizen in late
February 2001 that Mr. Drizen was purchasing shares of L.A.M.'s common stock in
an effort to stabilize L.A.M.'s stock price. However, Dr. Rothbart did not know
until May 11, 2001 that Mr. Drizen was using corporate funds for this purpose.
Gary Nath, an officer and director of L.A.M., and Joseph Slechta, an officer of
L.A.M., were not aware of Mr. Drizen's activities in this regard until May 11,
2001. Dr. Rothbart, Mr. Slechta and Mr. Nath became aware of Mr. Drizen's
borrowings from L.A.M. in connection with Mr. Slechta's review of L.A.M.'s
financial statements for the quarter ended March 31, 2001.

Mr. Drizen agreed to pay the $1,075,000 borrowed from L.A.M., together
with interest at 6% per year, in accordance with the terms of a promissory note.
The note provided for a series of periodic payments with the unpaid amount of
the note, together with any accrued and unpaid interest, due on March 31, 2002.
On May 25, 2001 L.A.M.'s Directors approved these repayment terms, and at the
same time ratified Mr. Drizen's borrowings from L.A.M.

Although Mr. Drizen agreed to secure the repayment of this note, L.A.M.'s
Board of Directors, in view of the fact that proceeds from the sale of Mr.
Drizen's shares of L.A.M.'s common stock would be the primary source of funds
which would be used to repay the Note, did not require Mr. Drizen to secure the
repayment of the Note. Accordingly, the Note from Mr. Drizen was unsecured.

In addition, as a result of Mr. Drizen's purchases and sales of L.A.M.'s
common stock between October 2000 and May 2001, L.A.M. is entitled to a
recoverable profit from Mr. Drizen, computed in accordance with 16(b) of the
Securities Exchange Act of 1934, in the amount of $408,078, as explained below.

During 2002 Mr. Drizen and L.A.M. agreed that the advance of $548,361 due
to him as of December 31, 2001 would be offset against the remaining amount due
pursuant to Mr. Drizen's promissory note. In addition, Dr. Rothbart and Mr. Nath
agreed with Mr. Drizen to apply a portion of their receivables from L.A.M.
against the amounts due by Mr. Drizen in an amount sufficient to offset the
remaining balance due on Mr. Drizen's promissory note.

Following these offset arrangements, as of December 31, 2002 L.A.M. owed
Dr. Rothbart and Mr. Nath $17,500 and $146,537 respectively, and Mr. Drizen's
promissory note was paid in full.

Section 16(b) of the Exchange Act allows a corporation to recover any
profits realized by officers, directors, and principal shareholders of a
corporation from the purchase and sale (or sale and purchase) of equity
securities of the corporation within a six-month period. Although Section 16(b)
was designed to prevent the unfair use of information that may have been
obtained by insiders through their relationship to a corporation, Section 16(b)

nevertheless imposes strict liability which does not depend upon the actual use
or possession of inside information by an insider.

The formula most frequently used by a corporation to recover profits is
known as the "lowest price in/highest price out" method, by which profit is
computed by matching the highest sale price with the lowest purchase price
within six months, the next highest sale price with the next lowest purchase
price within six months, and so forth, until all shares have been included in
the computation. Although this profit computation allows for the maximum
recovery to the corporation, in the case of multiple sales and purchases within
a six month period, it often results in a higher profit than the profit actually
realized by the insider, and in some cases may result in a profit when the
insider actually incurred losses from the sales and purchases. Mr. Drizen, for
example, estimates that he incurred a loss of approximately $900,000 as a result
of his purchases and sales of L.A.M.'s common stock between October 2000 and May
2001.

As of September 30, 2002 Mr. Drizen, a former officer and director of
L.A.M., owed L.A.M. $627,000, representing the unpaid portion of the exercise
price of options exercised by Mr. Drizen. Pursuant to the terms of an
agreement with Mr. Drizen, L.A.M. forgave the $627,000 owed by Mr. Drizen.

During the three months ended September 30, 2003 L.A.M. issued 2,367,000
shares of common stock, plus warrants for the purchase of 1,775,250 shares, in
payment of amounts owed by L.A.M. to five persons, including L.A.M.'s officers
and directors who received the shares of common stock and warrants shown below
in payment of amounts owed to these persons by L.A.M.

Shares Issuable Upon Debt
Name Shares Exercise of Warrants Satisfied

Joseph Slechta 625,000 468,750 $ 75,000
Peter Rothbart 625,000 468,750 $ 75,000
Gary Nath 875,000 656,250 $105,000

The shares shown in this table are part of the shares which are being
offered by means of this prospectus.

PRINCIPAL SHAREHOLDERS

The following table sets forth certain information as of October 31, 2003
concerning the common stock owned by each officer and director of L.A.M., and
each other person known to L.A.M. to be the beneficial owner of more than five
percent (5%) of L.A.M.'s common stock.

Amount and Nature of
Beneficial Ownership Percentage
Name Number of Shares (1) Ownership

Joseph T. Slechta 20,000 Nil
800 Sheppard Avenue West,
Commercial Unit 1
Toronto, Ontario
Canada M3H 6B4

Peter Rothbart 2,279,924 (2) 5.6%
274 St. Clements Avenue
Toronto, Ontario
Canada M4R 1H5

Gary M. Nath 2,122,942 5.2%
6106 Goldtree Way,
Bethesda, Maryland 20817

(All Officers and Directors as 4,422,866 10.8%
a group, 3 persons)

(1) Excludes shares issuable upon the exercises of options held by the
following persons:

Shares Issuable Upon Option Expiration
Name Exercise of Options Exercise Price Date of Option

Joseph T. Slechta 600,000 $0.58 06/05/06
Joseph T. Slechta 3,000,000 $0.58 06/30/11
Joseph T. Slechta 100,000 $0.58 01/18/08
Peter Rothbart 300,000 $0.58 06/05/06
Peter Rothbart 70,000 $0.58 01/18/08

(2) Includes shares held by the Shasqua Trust, of which Dr. Rothbart may be
deemed the beneficial owner.

SELLING SHAREHOLDERS

This prospectus relates to the sale of shares of L.A.M.'s common stock by
a number of shareholders of L.A.M. The shares offered by this prospectus include
shares owned by these shareholders as well as shares issuable upon the exercise
of warrants. The shares and warrants were issued by L.A.M. in a private offering
for cash, for services rendered, and in settlement of amounts owned by L.A.M.

L.A.M. will not receive any proceeds from the sale of the shares by the
selling shareholders. The selling shareholders may resell the shares they

acquire by means of this prospectus from time to time in the public market. The
costs of registering the shares offered by the selling shareholders are being
paid by L.A.M. The selling shareholders will pay all other costs of the sale of
the shares offered by them.

The following table identifies the selling shareholders and the shares which
they are offering for sale.
Shares Shares
Issuable to be Share
Upon the Sold in Ownership
Shares Exercise of this After
Name Owned Warrants Offering Offering

Bangratz, Rene 100,000 75,000 175,000 --
Brunner, Joachim 34,000 25,500 59,500 --
Buckhus, Kathrin 40,000 30,000 70,000 --
Capital Research
Group, Inc. 3,059,363 (1) 1,500,000 4,559,363 --
Casbey, Nigel 50,000 37,500 87,500 --
Casselman, Neil 60,000 45,000 105,000 --
Cornet, Corrine 25,000 18,750 43,750 --
Dupont, Pascal 25,000 18,750 43,750 --
Ebert, Sven 700,000 525,000 1,225,000 --
Emmett, John 170,000 112,500 262,500 20,000
Ernotte, Michel 30,000 22,500 52,500 --
Engelbrecht, John C. 300,000 225,000 525,000 --
Fassotte, Robert 77,000 57,750 134,750 --
Fazio, Antonia 1,250,000 937,500 2,187,500 --
Fazio, Antonia 344,828 -- 344,828 --
Gareth, Ellis 90,000 37,500 87,500 40,000
Gleitsmann, Daniel 15,000 11,250 26,250 --
Goschka, Mario 15,000 11,250 26,250 --
Gaus, Martin 35,000 26,250 61,250 --
Hamdan, Ahmad 40,000 30,000 70,000 --
Henrion, Jacques 28,000 21,000 49,000 --
Homan, Monique Antoinette 590,000 442,500 1,032,500 --
Huhn, Joseph 53,000 39,750 92,750 --
Lentini, Chiara 12,000 9,000 21,000 --
Langenberg, Peter 200,000 -- 200,000 --
Malay, Pierre 40,000 30,000 70,000 --
Marchal, Paul 50,000 -- 50,000 --
Mersky, Harold 50,000 37,500 87,500 --
Nath, Gary 2,997,942 656,250 1,531,250 2,122,942
Piasetzki & Nenniger 110,000 82,500 192,500 --
Pichot-Renard, Claudine 20,000 15,000 35,000 --
Rodenbourg, Jean-Paul 90,000 67,500 157,500 --
Rommes, Sonja 300,000 225,000 525,000 --
Rothbart, Peter 2,904,924 468,750 1,093,750 2,279,924
Schmitz, Rene 40,000 30,000 70,000 --

Shares Shares
Issuable to be Share
Upon the Sold in Ownership
Shares Exercise of this After
Name Owned Warrants Offering Offering

Schweizer, Joerg 172,000 129,000 301,000 --
Schweizer, Joerg 31,500 -- 31,500 --
Seil, Joseph 182,560 -- 182,560 --
Simon, Buehler 20,000 15,000 35,000 --
Simone, Romeo 10,000 7,500 17,500 --
Slechta, Joseph 645,000 468,750 1,093,750 20,000
Slome, Arnold 30,000 22,500 52,500 --
Slome, Jack 30,000 22,500 52,500 --
Slome, Martin 30,000 22,500 52,500 --
Speal, Edward 80,000 60,000 140,000 --
Swartz, Stan 80,000 60,000 140,000 --
Vespa, Anthony 40,000 -- 40,000 --
Voigt, Mathias 36,000 27,000 63,000 --
Wurm, Alexander 30,000 22,500 52,500 --
Zaccaro, Jocelyne 25,000 18,750 43,750 --
----------- ------------
6,747,750 17,653,001

The warrants referred to in the table above are exercisable upon the following
terms:

Shares Issuable Upon Warrant Expiration
Exercise of Warrants Exercise Price Date

1,749,250 $0.30 2/28/05
1,749,250 $0.30 8/31/05
1,749,250 $0.50 2/28/06
1,000,000 $0.22 3/2404
500,000 (2) $0.01 3/24/04

(1) These shares will be issued by L.A.M. on the date of this prospectus. See
Note E to the "Comparative Share Data" table.

(2) The issuance of any shares upon the exercise of this warrant is contingent
upon factors discussed in Note E to the "Comparative Share Data" table.

Manner of Sale.

The selling stockholders and any of their pledgees, assignees and
successors-in-interest may, from time to time, sell any or all of their shares
of common stock on any stock exchange, market or trading facility on which the
shares are traded or in private transactions. These sales may be at fixed or
negotiated prices. The selling stockholders may use any one or more of the
following methods when selling shares:

o ordinary brokerage transactions and transactions in which the
broker-dealer solicits purchasers;

o block trades in which the broker-dealer will attempt to sell the shares as
agent but may position and resell a portion of the block as principal to
facilitate the transaction;

o purchases by a broker-dealer as principal and resale by the
broker-dealer for its account;

o an exchange distribution in accordance with the rules of the applicable
exchange;

o privately negotiated transactions;

o short sales

o broker-dealers may agree with the Selling Stockholders to sell a
specified number of such shares at a stipulated price per share;

o a combination of any such methods of sale; and

o any other method permitted pursuant to applicable law.

The selling stockholders may also sell shares under Rule 144 under the
Securities Act, if available, rather than under this prospectus. Broker-dealers
engaged by the Selling Stockholders may arrange for other brokers-dealers to
participate in sales. Broker-dealers may receive commissions or discounts from
the selling stockholders (or, if any broker-dealer acts as agent for the
purchaser of shares, from the purchaser) in amounts to be negotiated. The
selling stockholders do not expect these commissions and discounts to exceed
what is customary in the types of transactions involved.

The selling stockholders may from time to time pledge or grant a security
interest in some or all of the shares of common stock owned by them and, if they
default in the performance of their secured obligations, the pledgees or secured
parties may offer and sell the shares of common stock from time to time under
this prospectus, or under an amendment to this prospectus under Rule 424(b)(3)
or other applicable provision of the Securities Act of 1933 amending the list of
selling stockholders to include the pledgee, transferee or other successors in
interest as selling stockholders under this prospectus.

The selling stockholders also may transfer the shares of common stock in
other circumstances, in which case the transferees, pledgees or other successors
in interest will be the selling beneficial owners for purposes of this
prospectus.

The selling stockholders and any broker-dealers or agents that are
involved in selling the shares may be deemed to be "underwriters" within the
meaning of the Securities Act in connection with such sales. In such event, any
commissions received by such broker-dealers or agents and any profit on the
resale of the shares purchased by them may be deemed to be underwriting
commissions or discounts under the Securities Act. The selling stockholders have

informed L.A.M. that they do not have any agreement or understanding, directly
or indirectly, with any person to distribute the common stock.

L.A.M. is required to pay all fees and expenses incident to the
registration of the shares. L.A.M. has agreed to indemnify the selling
stockholders against certain losses, claims, damages and liabilities, including
liabilities under the Securities Act.

L.A.M. has advised each selling shareholder that in the event of a
"distribution" of the shares owned by the selling shareholder, such selling
shareholder, any "affiliated purchasers", and any broker/dealer or other person
who participates in such distribution may be subject to Rule 102 under the
Securities Exchange Act of 1934 ("1934 Act") until their participation in that
distribution is completed. Rule 102 makes it unlawful for any person who is
participating in a distribution to bid for or purchase stock of the same class
as is the subject of the distribution. A "distribution" is defined in Rule 102
as an offering of securities "that is distinguished from ordinary trading
transactions by the magnitude of the offering and the presence of special
selling efforts and selling methods". L.A.M. has also advised the selling
shareholders that Rule 101 under the 1934 Act prohibits any "stabilizing bid" or
"stabilizing purchase" for the purpose of pegging, fixing or stabilizing the
price of the common stock in connection with this offering.

DESCRIPTION OF SECURITIES
Common Stock

L.A.M. is authorized to issue 50,000,000 shares of common stock. As of
October 14, 2003 L.A.M. had 41,309,206 outstanding shares of common stock, which
includes shares offered by this prospectus. Holders of common stock are each
entitled to cast one vote for each share held of record on all matters presented
to shareholders. Cumulative voting is not allowed; hence, the holders of a
majority of the outstanding common stock can elect all directors.

Holders of common stock are entitled to receive such dividends as may be
declared by the Board of Directors out of funds legally available therefore and,
in the event of liquidation, to share pro rata in any distribution of L.A.M.'s
assets after payment of liabilities. The Board of Directors is not obligated to
declare a dividend and it is not anticipated that dividends will be paid until
L.A.M. is in profit.

Holders of common stock do not have preemptive rights to subscribe to
additional shares if issued by L.A.M. There are no conversion, redemption,
sinking fund or similar provisions regarding the common stock.

Convertible Notes and Warrants

In November 2002, L.A.M. sold convertible notes, plus Series A, B, C and D
warrants, to a group of private investors for $700,000. The notes do not bear
interest, are unsecured and are payable on November 1, 2005.

At the holder's option the notes are convertible into shares of L.A.M.'s
common stock equal in number to the amount determined by dividing each $1,000 of
note principal to be converted by the Conversion Price. The Conversion Price as
of October 31, 2003 was $0.12.

As of October 31, 2003 notes in the principal amount of $589,600 had been
converted into 2,225,041 shares of L.A.M.'s common stock.

Each note holder is prohibited from converting the notes to the extent
that such conversion would result in such holder, together with any affiliate of
the holder, beneficially owning in excess of 4.999% of the outstanding shares of
L.A.M.'s common stock following such conversion. This restriction may be waived
by each holder on not less than 61 days' notice to L.A.M. However, the 4.999%
limitation would not prevent each note holder from acquiring and selling in
excess of 4.999% of L.A.M.'s common stock through a series of acquisitions and
sales so long as the holder never beneficially owns more than 4.999% of L.A.M.'s
common stock at any one time.

L.A.M. has agreed to file a registration statement with the Securities and
Exchange Commission in order that the shares of common stock issuable upon the
conversion of the notes or the exercise of the warrants may be resold in the
public market.

Until 180 days after the date of this prospectus the note holders will
have a first right of refusal to participate in any subsequent financings
involving L.A.M.

Upon the occurrence of any of the following events L.A.M. is required to
redeem the notes at a price equal to 120% of then outstanding principal balance
of the notes:

- - the suspension from listing or the failure of L.A.M.'s common stock
to be listed on the OTC Bulletin Board for a period of five
consecutive trading days; or

- the effectiveness of the registration statement lapses for any reason
or the registration statement is unavailable to the note holders and
the lapse or unavailability continues for a period of fifteen
consecutive trading days, or 25 non-consecutive trading days during
any twelve month period, provided the cause of the lapse or
unavailability is not due to factors primarily within the control of
the note holders.

- any representation or warranty made by L.A.M. to the note holders
proves to be materially inaccurate or L.A.M. fails to perform any
material covenant or condition in its agreement with the note
holders.

- a purchase, tender or exchange offer accepted by the holders of more
than 33% of L.A.M.'s outstanding shares of common stock.

- L.A.M. files for protection from its creditors under the federal
bankruptcy code.

The Series A warrants allow the holders to purchase 411,522 shares of
L.A.M.'s common stock at a price of $0.12 per share at any time prior to
November 1, 2007.

The Series B warrants allow the holders to purchase 1,312,500 shares of
L.A.M.'s common stock at a price of $0.80 per share at any time prior to
November 1, 2007. Within two days after the end of any period of ten consecutive
days that the closing bid price of L.A.M.'s common stock has exceeded $1.20,
L.A.M. has the right, upon 15 days advance written notice to the holders of the
Series B warrants, to force the holders to exercise the unexercised portion of
the Series B warrants.

The Series C warrants allow the holders to purchase 875,000 shares of
L.A.M.'s common stock at a price of $1.20 per share at any time prior to
November 1, 2007. Within two days after the end of any period of ten consecutive
days that the closing bid price of L.A.M.'s common stock has exceeded $2.00,
L.A.M. has the right, upon 15 days advance written notice to the holders of the
Series C warrants, to force the holders to exercise the unexercised portion of
the Series C warrants.

The Series D warrants allow the holders to purchase 656,250 shares of
L.A.M.'s common stock at a price of $1.60 per share at any time prior to
November 1, 2007. Within two days after the end of any period of ten consecutive
days that the closing bid price of L.A.M.'s common stock has exceeded $2.50,
L.A.M. has the right, upon 15 days advance written notice to the holders of the
Series D warrants, to force the holders to exercise the unexercised portion of
the Series D warrants.

L.A.M.'s right to force the warrant holders to exercise the Series, B, C
and D warrants is subject to a number of conditions, including the following:

- - there is in effect a registration statement which the holders may use to
sell the shares issuable upon the exercise of the warrants.

- - L.A.M.'s common stock is listed for trading on the OTC Bulletin Board

The exercise price of the Series B, C and D warrants is not subject to
adjustment except in the case of stock splits, consolidations and similar
transactions.

Each warrant holder is prohibited from exercising the warrants to the
extent that such exercise would result in such holder, together with any
affiliate of the warrant holder, beneficially owning in excess of 4.999% of the
outstanding shares of L.A.M.'s common stock following such exercise. This
restriction may be waived by each holder on not less than 61 days' notice to
L.A.M. However, the 4.999% limitation would not prevent each warrant holder from
acquiring and selling in excess of 4.999% of L.A.M.'s common stock through a

series of acquisitions and sales under the warrants so long as the warrant
holder never beneficially owns more than 4.999% of L.A.M.'s common stock at any
one time.

Transfer Agent

Corporate Stock Transfer, Inc.
3200 Cherry Creek Drive South, Suite 430
Denver CO, 80209
Telephone Number (303)-282-4800
Facsimile Number (303) 282-5800

LEGAL PROCEEDINGS

L.A.M. is not involved in any pending or threatened legal proceeding. See
"Comparative Share Data - Note E" for information concerning the settlement of
an arbitration award entered against L.A.M.

EXPERTS

The financial statements included in this prospectus for the years ended
December 31, 2002 and 2001 have been so incorporated in reliance on the report
of Rotenberg & Company, LLP, independent accountants, given on authority of said
firm as experts in auditing and accounting.

INDEMNIFICATION

L.A.M.'s Bylaws authorize indemnification of a director, officer, employee
or agent of L.A.M. against expenses incurred by him in connection with any
action, suit, or proceeding to which he is named a party by reason of his having
acted or served in such capacity, except for liabilities arising from his own
misconduct or negligence in performance of his duty. In addition, even a
director, officer, employee, or agent of L.A.M. who was found liable for
misconduct or negligence in the performance of his duty may obtain such
indemnification if, in view of all the circumstances in the case, a court of
competent jurisdiction determines such person is fairly and reasonably entitled
to indemnification. Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to directors, officers, or persons
controlling L.A.M. pursuant to the foregoing provisions, L.A.M. has been
informed that in the opinion of the Securities and Exchange Commission, such
indemnification is against public policy as expressed in the Act and is
therefore unenforceable.

AVAILABLE INFORMATION

L.A.M. is subject to the informational requirements of the Securities
Exchange Act of l934 and in accordance therewith is required to file reports,
proxy statements and other information with the Securities and Exchange
Commission (the "Commission"). Copies of any such reports, proxy statements and
other information filed by L.A.M. can be inspected and copied at the public
reference facility maintained by the Securities and Exchange Commission at Room
1024, 450 Fifth Street, N.W., Washington, D.C. Copies of such material can be
obtained from the Public Reference Section of the Securities and Exchange

Commission at its office in Washington, D.C. 20549 at prescribed rates. Certain
information concerning L.A.M. is also available at the Internet Web Site
maintained by the Securities and Exchange Commission at www.sec.gov. L.A.M. has
filed with the Securities and Exchange Commission a Registration Statement on
Form SB-2 (together with all amendments and exhibits) under the Securities Act
of 1933, as amended (the "Act"), with respect to the Securities offered by this
prospectus. This prospectus does not contain all of the information set forth in
the Registration Statement, certain parts of which are omitted in accordance
with the rules and regulations of the Securities and Exchange Commission. For
further information, reference is made to the Registration Statement.

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

-------------------------------------
FINANCIAL REPORTS
AT
DECEMBER 31, 2002
-------------------------------------

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

TABLE OF CONTENTS
- ------------------------------------------------------------------------------

Independent Auditors' Report F-2

Balance Sheets at December 31, 2002 and 2001 F-3

Statements of Changes in Stockholders' Deficit for the Years Ended
December 31, 2002 and 2001 F-4 to F-5

Statements of Operations for the Years Ended December 31, 2002
and 2001 F-6

Statements of Cash Flows for the Years Ended December 31, 2002
and 2001 F-7 to F-8

Notes to Financial Statements F-9 to F-21

INDEPENDENT AUDITORS' REPORT

To the Board of Directors
and Shareholders
L.A.M. Pharmaceutical, Corp. Lewiston, New York

We have audited the accompanying balance sheets of L.A.M. Pharmaceutical,
Corp. (A Delaware Corporation) as of December 31, 2002 and 2001, and the related
statements of changes in stockholders' deficit, operations and cash flows for
each of the two years in the period ended December 31, 2002. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.

We conducted our audits in accordance with auditing standards generally
accepted in the United States of America. Those standards require that we plan
and perform the audits to obtain reasonable assurance about whether the
financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as
evaluating the overall presentation of the financial statements. We believe that
our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly,
in all material respects, the financial position of L.A.M. Pharmaceutical, Corp.
(A Delaware Corporation) as of December 31, 2002 and 2001 and the results of its
operations and its cash flows for each of the two years in the period ended
December 31, 2002, in conformity with accounting principles generally accepted
in the United States of America.

Rotenberg & Co., LLP
Rochester, New York
February 27, 2003
(Except for Note O, as to which the date is March 27, 2003)

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

BALANCE SHEETS
- --------------------------------------------------------------------------------
December 31, 2002 2001
- --------------------------------------------------------------------------------

ASSETS

Current Assets
Cash and Cash Equivalents $ 210,214 $11,284
Accounts Receivable 13,643 --
Other Receivable -- 44,433
Inventory 550,085 97,750
Prepaid Expenses 6,686 5,344
- --------------------------------------------------------------------------------
Total Current Assets 780,628 158,811

Property and Equipment - Net of Accumulated
Depreciation 124,958 121,185

Other Assets
Patents and Trademarks - Net of Accumulated
Amortization 546,631 489,322
- --------------------------------------------------------------------------------
Total Assets $1,452,217 $ 769,318
- --------------------------------------------------------------------------------

LIABILITIES AND STOCKHOLDERS' DEFICIT

Current Liabilities
Accounts Payable and Accrued Expenses $ 866,164 $ 601,999

Convertible Notes 671,000 -
- --------------------------------------------------------------------------------

Total Current Liabilities 1,537,164 601,999

Other Liabilities

Due to Stockholders 164,037 848,037

Deferred Royalty Revenue 207,360 207,360
- --------------------------------------------------------------------------------

Total Liabilities 1,908,561 1,657,396
- --------------------------------------------------------------------------------

Stockholders' Deficit
Common Stock - $.0001 Par; 50,000,000 Authorized;
27,511,412 and 19,784,520 Issued and
Outstanding, respectively 2,751 1,978

Additional Paid-In Capital 24,054,187 17,964,009

Loan Receivable-Director/Officer -- (640,000)

Deficit Accumulated During Development Stage (24,513,282) (18,214,065)
- --------------------------------------------------------------------------------

Total Stockholders' Deficit (456,344) (888,078)
- --------------------------------------------------------------------------------

Total Liabilities and Stockholders' Deficit $1,452,217 $ 769,318
- --------------------------------------------------------------------------------

The accompanying notes are an integral part of these financial statements.

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT

- ----------------------------------------------------------------------------------------------------------------------------
Additional Loan Total
Number Common Paid-In Receivable- Accumulated Stockholders'
of Shares Stock Capital Director/Office Deficit Deficit
- ----------------------------------------------------------------------------------------------------------------------------

Balance - December 31, 2000 13,998,930 $ 1,400 $8,812,199 $ -- $(9,815,305) $(1,001,706)

Capital Contribution - Interest Expense -- -- 113,200 -- -- 113,200

Common Shares Issued - Debenture Conversion
Premium 3,106,502 311 1,057,844 -- -- 1,058,155

Debentures Converted to Common Stock 853,167 85 1,611,114 -- -- 1,611,199

Stock Options Issued
- Compensation for Services Rendered -- -- 3,218,463 -- -- 3,218,463

Common Shares Issued
- Compensation for Services Rendered 1,213,900 121 1,047,086 -- -- 1,047,207

Stock Options Exercised 173,000 17 112,433 -- -- 112,450

Warrants Issued to Hockbury Limited and GKN
Securities -- -- 1,100,000 -- -- 1,100,000

Sale of Shares Under the Equity Line of
Credit Agreement 439,021 44 483,592 -- -- 483,636

Loan to Officer -- -- -- (1,075,000) -- (1,075,000)

Loan Repayments from Officer -- -- -- 435,000 -- 435,000

Short-Swing Profit on Insider Trading -- -- 408,078 -- -- 408,078

Net Loss -- -- -- -- (8,398,760) (8,398,760)
- ---------------------------------------------------------------------------------------------------------------------------------

Balance - December 31, 2001 19,784,520 $ 1,978 $17,964,009 $(640,000) $(18,214,065) $ (888,078)

The accompanying notes are an integral part of these financial statements.

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

Balance - December 31, 2001 19,784,520 $ 1,978 $17,964,009 $ (640,000) $(18,214,065) $(888,078)

Capital Contribution - Interest Expense -- -- 19,264 -- -- 19,264

Common Shares Issued - Note Conversion
Premium -- -- 204,762 -- -- 204,762

Notes Converted to Common Stock 98,640 10 28,990 -- -- 29,000

Warrants Issued - Convertible Notes -- -- 55,543 -- -- 55,543

Stock Options Issued
- Compensation for Services Rendered -- -- 1,394,752 -- -- 1,394,752

Common Shares Issued
- Compensation for Services Rendered 1,821,500 182 979,694 -- -- 979,876

Stock Options Exercised 4,933,975 494 2,869,896 -- -- 2,870,390

Sale of Shares Under the Equity Line of
Credit Agreement 614,156 61 487,303 -- -- 487,364

Sale of Shares Under the Private Placement
Memorandum 258,621 26 74,974 -- -- 75,000

Receivable on Option Exercise -- -- (25,000) -- -- (25,000)

Loan Repayments from Officer -- -- -- 640,000 -- 640,000

Net Loss -- -- -- -- (6,299,217) (6,229,217)
- ------------------------------------------------------------------------------------------------------------------------------

Balance - December 31, 2002 27,511,412 $2,751 $24,054,187 $ -- $(24,513,282) $ (456,344)
- ------------------------------------------------------------------------------------------------------------------------------

The accompanying notes are an integral part of these financial statements.

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

STATEMENTS OF OPERATIONS

- ----------------------------------------------------

Years ended December 31, 2002 2001
- ----------------------------------------------------------------

Revenues
Licensing Revenue $ -- $ 300,000
Net Sales 40,160 --
- ----------------------------------------------------------------
40,160 300,000
- ----------------------------------------------------------------

Expenses
Cost of Sales 10,250 --
General and Administrative 1,972,329 1,378,791
Marketing and Business Development 975,077 201,808
Research and Development 572,617 479,881
- ----------------------------------------------------------------
3,530,273 2,060,480
Financial Accounting Expenses
Not Requiring the Use of Cash During the
Period:
Depreciation and Amortization 60,928 27,159
Interest Expense 19,942 232,819
Share and Option Grants to Officers,
Directors

Investors and Consultants 2,467,929 4,265,670
Conversion Premium on Convertible
Notes 204,762 1,057,844
Warrants Issued 55,543 1,100,000
- ----------------------------------------------------------------

Total Expenses 6,339,377 8,743,972
- ----------------------------------------------------------------

Loss Before Other Income and
(Expenses) (6,299,217) (8,443,972)
- ----------------------------------------------------------------

Other Income and (Expenses)
Interest Income -- 45,212
- ----------------------------------------------------------------

Total Other Income and (Expenses) -- 45,212
- ----------------------------------------------------------------

Net Loss for the Period $(6,299,217) $(8,398,760)
- ----------------------------------------------------------------

Loss per Common Share - Basic and
Diluted $ (0.26) $ (0.53)
- ----------------------------------------------------------------

Weighted Average Number
of Common Shares Outstanding -
Basic and Diluted 24,644,912 15,817,111
- ----------------------------------------------------------------

The accompanying notes are an integral part of these financial statements.

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

STATEMENTS OF CASH FLOWS
-----------------------------------------------------------------------------
Years ended December 31, 2002 2001
-----------------------------------------------------------------------------

Cash Flows from Operating Activities

Net Loss $(6,299,217) $(8,398,760)

Adjustments to Reconcile Net Loss for the
Period to Cash Flows from Operating
Activities:
Depreciation and Amortization 60,928 27,159
Write-off of receivable 627,000 --
Capital Contributions:
Deemed Interest Expense on Loans from
Stockholders 19,264 113,200
Share and Option Grants - Officers,
Directors Investors and Consultants 2,558,328 4,265,670
Warrants Issued 55,543 1,100,000
Conversion Premium on Convertible
Notes 204,762 1,058,155
Interest on Converted Debentures -- 121,449

Changes in Assets and Liabilities:
Accounts Receivable (13,643) 30,567
Inventory (452,335) 23,375
Prepaid Expenses (1,342) (2,705)
Accounts Payable and Accrued Expenses 548,365 204,515
-----------------------------------------------------------------------------

Net Cash Flows from Operating Activities (2,692,347) (1,457,375)
-----------------------------------------------------------------------------

Cash Flows from Investing Activities
Purchases of Property and Equipment (26,841) (112,508)
Purchases of Patents and Trademarks, Net (95,169) (169,361)
-----------------------------------------------------------------------------

Net Cash Flows from Investing Activities (122,010) (281,869)
-----------------------------------------------------------------------------
-continued-

The accompanying notes are an integral part of these financial statements.

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

STATEMENTS OF CASH FLOWS - continued
-----------------------------------------------------------------------------
Years ended December 31, 2002 2001
-----------------------------------------------------------------------------

Cash Flows from Financing Activities
Proceeds from Issuance of Common Stock 75,000 --
Proceeds from Convertible Notes 700,000 --
Proceeds from Exercise of Stock Options 1,750,490 112,450
Proceeds from Sale of Shares Under
the Equity Line of Credit Agreement 487,364 483,636
Issuance of Loan Receivable - Officer, Net -- (640,000)
Repayment of Convertible Notes -- (108,500)
Advances from Stockholders 433 --
------------------------------------------------------------------------------

Net Cash Flows from Financing Activities 3,013,287 (152,414)
------------------------------------------------------------------------------

Net Change
in Cash and Cash Equivalents 198,930 (1,891,658)

Cash and Cash Equivalents - Beginning of
Period 11,284 1,902,942
------------------------------------------------------------------------------

Cash and Cash Equivalents - End of Period $ 210,214 $ 11,284
------------------------------------------------------------------------------

NON-CASH INVESTING AND FINANCING ACTIVITIES
-----------------------------------------------------------------------

Offsetting of Stockholders Receivable
and Payable $ 728,000 $ --
Short-Swing Profit on Insider Trading
- Offset Against Loan Payable to
Shareholder $ -- $ 408,078
$ -- $1,489,750
Debentures Converted to Common Stock
Exercise of Stock Options $ 835,700 $ --
------------------------------------------------------------------------------

SUPPLEMENTAL DISCLOSURE
------------------------------------------------------------------------------

Interest Paid $ -- $ --
Income Taxes Paid $ -- $ --
------------------------------------------------------------------------------

The accompanying notes are an integral part of these financial statements.

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

NOTES TO FINANCIAL STATEMENTS
- ------------------------------------------------------------------------------

Note A - Summary of Transaction
L.A.M. Pharmaceutical, Corp. (the Company) was initially formed as
L.A.M. Pharmaceutical, LLC (the LLC) on February 4, 1997. From February
1, 1994 to February 4, 1997 the Company conducted its activities under
the name RDN. In September 1998, the members of L.A.M. Pharmaceuticals
LLC, a Florida Limited liability company, exchanged all of their
interests in the LLC for 6,000,000 shares of the Company's common stock.
The stock exchange between the Company and the members of the LLC is
considered a recapitalization or reverse acquisition. Under reverse
acquisition accounting, the LLC was considered the acquirer for
accounting and financial reporting purposes, and acquired the assets and
assumed the liabilities of the Company. The accompanying financial
statements include the historical accounts of the Company, the LLC and
RDN since February 1, 1994. All intercompany accounts and transactions
have been eliminated.

Note B - Nature of Operations and Summary of Significant Accounting Policies
L.A.M. Pharmaceutical, Corp. was incorporated on July 24, 1998 under
the laws of the State of Delaware. The Company has the authority to
issue 50,000,000 shares of common stock, $.0001 par value. The
Company's corporate objective is to develop, market andn license wound
healing and transdermally delivered drugs, both prescription and
over-the-counter, using the Company's patented L.A.M. Ionic Polymer
Matrix TM technology. The Company currently serves the healthcare
market in the USA.

Development Stage
In August 2002, the Company commenced sales of its L.A.M. IPM Wound
Gel(TM) and as a result has revised its presentation of the financial
statements from a development stage company to that of an operating
company.

Revenue Recognition
The Company recognizes revenue when it is realized or realizable and
earned. The Company considers revenue realized or realizable when the
product has been shipped to the customer, the sales price is fixed or
determinable and collectibility is reasonably assured. The Company
reduces revenue for estimated customer returns.

Royalty revenue on the exclusive world-wide license agreement (the
License Agreement) with Ixora Bio-Medical Company Inc. (Ixora) will be
recorded when received.

Method of Accounting
The Company maintains its books and prepares its financial statements on
the accrual basis of accounting.
- continued -

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

NOTES TO FINANCIAL STATEMENTS
- ------------------------------------------------------------------------------

Note B -Nature of Operations and Summary of Significant Accounting Policies -
continued

Use of Estimates
The preparation of financial statements in conformity with generally
accepted accounting principles in the United States of America requires
management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the date of the financial statements and the reported
amounts of revenues and expense during the reporting period. Actual
results can differ from those estimates.

Concentrations of Credit Risk
Financial instruments which potentially expose the Company to
significant concentrations of credit risk consist principally of bank
deposits. Cash is placed primarily in high quality short-term interest
bearing financial instruments.

Cash and Cash Equivalents
Cash and cash equivalents include time deposits, certificates of
deposit, and all highly liquid debt instruments with original maturities
of three months or less. The Company maintains cash and cash equivalents
at financial institutions that periodically may exceed federally insured
amounts.

Inventory
Inventory is comprised of finished goods and raw materials and is stated
at the lower of cost or market. Cost is determined by the first-in,
first-out method and market is based on the lower of replacement cost or
net realizable value.

Property, Equipment and Depreciation
Property and equipment are stated at cost, less accumulated depreciation
computed using the straight-line method over the estimated useful lives
as follows:

Furniture and Fixtures 5 - 7 Years
Computer Equipment 5 - 7 Years
Leasehold Improvements 5 Years

Maintenance and repairs are charged to expense as incurred. The cost of
the assets retired or otherwise disposed of and the related accumulated
depreciation are removed from the accounts.

Patents and Trademarks
Patents are carried at cost and are amortized using the straight-line
method over their estimated useful lives, not to exceed 17 years from
the date of issuance of the patent. Amortization expense for the years
ended December 31, 2002 and 2001 was $37,860 and $16,236,
respectively. Accumulated amortization associated with patents and
trademarks at December 31, 2002 and 2001 amounted to $89,767 and
$51,908, respectively. - continued -

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

NOTES TO FINANCIAL STATEMENTS
- ------------------------------------------------------------------------------

Note B - Nature of Operations and Summary of Significant Accounting
Policies - continued

Impairment of Assets
Effective January 1, 2002, the Company adopted the provisions of SFAS
No. 144, "Accounting for the Impairment or Disposal of Long Lived
Assets." This standard superceded SFAS No. 121, "Accounting for the
Impairment of Long Lived Assets and for Long Lived Assets to be Disposed
of," but also retained its basic provision requiring (i) recognition of
an impairment loss of the carrying amount of a long-lived asset if it is
not recoverable from its undiscounted cash flows and (ii) measurement of
an impairment loss as the difference between the carrying amount and
fair value of the asset unless an asset is held for sale, in which case
it would be stated at the lower of carrying amount or fair value less
costs to dispose. However, SFAS No. 144 also describes a
probability-weighted cash flow estimation approach to deal with
situations which alternative courses of action to recover the carrying
amount of a long-lived asset are under consideration or a range is
estimated. The determination of undiscounted cash flows requires
significant estimates made by management and considers the expected
course of action at the balance sheet date. Subsequent changes in
estimated undiscounted cash flows arising from changes in anticipated
actions could impact the determination of whether an impairment exists.

Management reviews its long-lived assets used in operations for
impairment when there is an event or change in circumstances that
indicates an impairment in value. An asset is considered impaired when
the undiscounted future cash flows are not sufficient to recover the
asset's carrying value. If such impairment is present, an impairment
loss is recognized based on the excess of the carrying amount of the
asset over its fair value

Research and Development Costs
Research and development expenditures are expensed as incurred.

Net Income (Loss) Per Common Share
Net income (loss) per common share is computed in accordance with SFAS No.
128, "Earnings Per Share". Basic earnings per common share is calculated
by dividing income available to common shareholders by the
weighted-average number of common shares outstanding for each period.
Diluted earnings per common share is calculated by adjusting the
weighted-average shares outstanding assuming conversion of all
potentially dilutive stock options, warrants and convertible securities.
Diluted earnings per share is the same as basic earnings per share for
all of the periods presented since the effect of the conversion of
debentures, stock options and warrants granted would have an
anti-dilutive effect on earnings per share.

Income Taxes
The Company accounts for income taxes in accordance with SFAS No. 109,
"Accounting for Income Taxes," using the asset and liability approach,
which requires recognition of deferred tax liabilities and assets for
the expected future tax consequences of temporary differences between
the carrying amounts and the tax basis of such assets and liabilities.
This method utilizes enacted statutory tax rates in effect for the year
in which the temporary differences are expected to reverse and gives
immediate effect to changes in income tax rates upon enactment. Deferred
tax assets are recognized, net of any valuation allowance, for temporary
differences and net operating loss and tax credit carryforwards.
Deferred income tax expense represents the change in net deferred assets
and liability balances.

- continued -

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

NOTES TO FINANCIAL STATEMENTS
- ------------------------------------------------------------------------------

Note B - Nature of Operations and Summary of Significant Accounting
Policies - continued

Share and Option Grants
As described in Note K, the Company has elected to follow the accounting
provisions of Accounting Principles Board Opinion (APBO) No. 25
"Accounting for Stock Issued to Employees", for stock-based compensation
and awards made to employees - the intrinsic value method. Pro forma
disclosures required under SFAS No. 123, "Accounting for Stock-Based
Compensation" has been furnished in Note K. Stock options granted to
investors and consultants are subject to the provisions of SFAS No. 123
and are recorded at the fair value of the option at the date of grant

Financial Instruments
The Company's financial instruments consist of cash, accounts receivable
and accounts payable. Unless otherwise noted, it is management's opinion
that the Company is not exposed to significant interest, currency or
credit risks arising from these financial instruments. The fair value of
these financial instruments approximates their carrying value, unless
otherwise noted.

The fair value of due to stockholders and loan receivable - officer
could not be obtained without incurring excessive costs as they have no
readily determinable market place.

New Pronouncements
In April 2002, the Financial Accounting Standards Board issued FASB
Statement No. 145, Rescission of FASB Statements No. 4, 44, and 64,
Amendment of FASB Statement No. 13, and Technical Corrections (SFAS
145). SFAS 145 requires that gains and losses from extinguishment of
debt be classified as extraordinary items only if they meet the criteria
in Opinion 30. Applying the provisions of Opinion 30 will distinguish
transactions that are part of an entity's recurring operations from
those that are unusual and infrequent and therefore meet the criteria
for classification as an extraordinary item. SFAS 145 also requires that
modifications to a capital lease that make it an operating lease be
accounted for, as applicable, in accordance with FASB Statement No. 98,
Accounting for Leases, or FASB Statement No. 28, Accounting for Sales
with Leasebacks. SFAS 145 is required to be applied in fiscal years
beginning after May 15, 2002 and to provisions relating to modifications
of a capital lease that make it an operating lease as of May 15, 2002.
Upon adoption of SFAS 145, gains and losses on debt extinguishment that
have been shown on the income statement as extraordinary items in prior
periods should be reclassified, unless they meet the criteria for
extraordinary status per Opinion 30. Management does not anticipate that
the adoption of SFAS 145 will have any material impact on the financial
statements.

In June 2002, the Financial Accounting Standards Board issued FASB
Statement No. 146, Accounting for Costs Associated with Exit or Disposal
Activities (SFAS 146). SFAS 146 addresses financial accounting and
reporting for costs associated with exit or disposal activities and
nullifies Emerging Issues Task Force Issue No. 94-3, Liability
Recognition for Certain Employee Termination Benefits and Other Costs to
Exit an Activity (including Certain Costs Incurred in a Restructuring).
SFAS 146 requires companies to recognize costs associated with exit or
disposal activities when they incurred rather than at the date of a
commitment to an exit or disposal plan. Costs covered by SFAS 146
include lease termination costs and certain employee severance costs
that are associated with a restructuring, discontinued operation, plant
closing, or other exit or disposal activity. SFAS 146 applies to all
exit or disposal activities initiated after December 31, 2002.
Management does not anticipate that the adoption of SFAS 146 will have
any material impact on the financial statement.

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

NOTES TO FINANCIAL STATEMENTS
- ------------------------------------------------------------------------------

Note C - Licensing Agreement
The Company has an exclusive license agreement (the License Agreement)
with Ixora Bio-Medical Company, Inc. (Ixora). Under the License
Agreement, Ixora has paid the Company $500,000 for the exclusive rights
of the Company's male and female sexual dysfunction product technology.
Ixora has also agreed to pay all costs for the development, registration
and protection of intellectual property, including but not limited to
patent costs, raw material costs, clinical development costs and
compensation of all Company personnel involved in the sexual dysfunction
product technology.

Note D -Inventory
Inventories at December 31 consisted of the following:

------------------------------------------------------------------------
2002 2001
------------------------------------------------------------------------

IPM Wound Gel(TM) $ 539,460 $ --
Raw Materials 10,625 97,750
------------------------------------------------------------------------

Inventories $ 550,085 $ 97,750
------------------------------------------------------------------------

Note E -Property and Equipment
Property and equipment are recorded at cost and consisted of the
following:

------------------------------------------------------------------------
December 31, 2002 2001
------------------------------------------------------------------------

Furniture and Fixtures $ 127,493 $ 122,101
Computer Equipment 43,544 22,095
Leasehold Improvements 30,692 30,692
------------------------------------------------------------------------
$ 201,729 $ 174,888
Less: Accumulated Depreciation (76,771) (53,703)
------------------------------------------------------------------------

Net Property and Equipment $124,958 $ 121,185
------------------------------------------------------------------------

Depreciation expense for the years ended December 31, 2002 and 2001 was
$23,068 and $10,923, respectively.

Note F - Due to Stockholders
The Company has a liability for cash advances and salaries and other
expenses incurred in earlier years due to its stockholders totaling
$164,037 and $848,037 at December 31, 2002 and 2001, respectively. The
Company has agreements with these stockholders, which provides for
payment of this obligation without interest, not to exceed 25% of the
profits realized by the Company in any year. The Company has imputed
interest at 5.75% in 2002 and 8.5% in 2001 and charged operations for
each of the periods presented with an offsetting credit to additional
paid-in capital.

Note G - Deferred Royalty Revenue
Deferred Royalty Revenue represents amounts due to the Company from
Ixora Biomedical pursuant to the worldwide license agreement. The
$207,360 of Deferred Royalty Revenue approximated the value of the
Company's original investment in the affiliate. The balance will be
amortized to income upon commencement of Ixora's sale of the Company's
products.

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

NOTES TO FINANCIAL STATEMENTS
- ------------------------------------------------------------------------------

Note H - Loan Receivable - Director
Between February and April 2001, Alan Drizen, the Company's former
President, borrowed $1,075,000 from the Company. The amounts borrowed
were used by Mr. Drizen to purchase shares of the Company's common stock
in an effort to stabilize the share price in the face of extensive short
selling of the shares.

Mr. Drizen had agreed to repay this amount to the Company, together with
interest at 6% per year, in accordance with the terms of a promissory
note. The note provided for a series of periodic payments with the
unpaid amount of the note, together with any accrued and unpaid
interest, due on March 31, 2002.

Although Mr. Drizen agreed to secure the repayment of this note, the
Company's Board of Directors, in view of the fact that proceeds from the
sale of Mr. Drizen's shares of the Company's common stock would be the
primary source of funds which would be used to repay the note, did not
require Mr. Drizen to secure the repayment of the note. Accordingly, the
note from Mr. Drizen was unsecured. During March 2002, Mr. Drizen and
the Company agreed that the balance of $548,361 owed by the Company to
Mr. Drizen at December 31, 2001, included in amounts due to
stockholders, would be offset against the remaining amount due pursuant
to Mr. Drizen's promissory note. In addition, two other Directors and
stockholders agreed with Mr. Drizen to apply a portion of their
receivables from the Company, included in amounts due to stockholders,
against the amounts due by Mr. Drizen in an amount sufficient to offset
the remaining balance due on Mr. Drizen's promissory note. Following
these offset arrangements, Mr. Drizen's promissory note was paid in
full.

As a result of Mr. Drizen's purchases and sales of the Company's common
stock between October 2000 and May 2001, the Company was entitled to a
recoverable profit of $408,078 from Mr. Drizen, computed in accordance
with Section 16(b) of the Securities Exchange Act of 1934. During 2001,
this amount was applied to reduce the amount that the Company owed to
Mr. Drizen with the offset being to additional paid-in capital.

During the year ended December 31, 2002, Mr. Drizen exercised options to
acquire 2,650,000 shares of the Company's common stock. The total
exercise price of these options was $1,537,000. Pursuant to the terms of
an agreement, signed in January 2003, with Mr. Drizen, the Company
forgave the $627,000 owed by Mr. Drizen and has charged the amount to
expense

Note I - Income Taxes
The components of the deferred tax asset (liability) at December 31 are
as follows:

------------------------------------------------------------------------
December 31, 2002 2001
------------------------------------------------------------------------

Net Operating Loss $2,188,479 $1,347,713
Stock Options 610,769 456,497
Patents 80,547 160,630
------------------------------------------------------------------------
Gross Deferred Tax Assets 2,879,795 1,347,713
------------------------------------------------------------------------
Property, Plant and Equipment (2,155) (1,367)
------------------------------------------------------------------------
Gross Deferred Tax Liabilities (2,155) (1,367)
------------------------------------------------------------------------
Net Deferred Tax Assets 2,877,640 1,963,473
------------------------------------------------------------------------
Valuation Allowance (2,877,640) (1,963,473)
Net Deferred Taxes $ -- $ --
------------------------------------------------------------------------

-continued-

- ------------------------------------------------------------------------------
L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

NOTES TO FINANCIAL STATEMENTS
- ------------------------------------------------------------------------------

Note I - Income Taxes - continued

The net operating loss carryforwards expire in varying amounts from 2013
to 2017. The Company has fully reserved for any future tax benefits from
the net operating loss carryforwards and net deferred tax assets since
it has not generated any revenues to date.

Note J - Convertible Notes
During 2002, L.A.M. sold convertible notes, plus Series A, B, C and D
warrants, to a group of private investors for $700,000. The notes do not
bear interest, are unsecured and are payable on November 1, 2005.

At the holder's option, the notes are convertible into shares of
L.A.M.'s common stock equal in number to the amount determined by
dividing each $1,000 of note principal to be converted by the Conversion
Price. The initial Conversion Price is $0.29.

If L.A.M. sells any additional shares of common stock, or any securities
convertible into common stock at a price below the then applicable
Conversion Price, the Conversion Price will be lowered to the price at
which the shares were sold or the lowest price at which the securities
are convertible, as the case may be.

Upon the occurrence of any of the following events, L.A.M. is required
to redeem the notes at a price equal to 120% of the then outstanding
principal balance of the notes:

- the suspension from listing or the failure of L.A.M.'s common stock to
be listed on the OTC Bulletin Board for a period of five consecutive
trading days; or

- the effectiveness of the registration statement lapses for any
reason or the registration statement is unavailable to the note holders
and the lapse or unavailability continues for a period of 15 consecutive
trading days, or 25 non-consecutive trading days during any 12 month
period, provided the cause of the lapse or unavailability is not due to
factors primarily within the control of the note holders.

- a purchase, tender or exchange offer accepted by the holders
of more than 33% of L.A.M.'s outstanding shares of common stock.

- L.A.M. files for protection from its creditors under the
federal Bankruptcy code.

The Series A warrants allow the holders to purchase 596,590 shares of
L.A.M.'s common stock at a price of $0.35 per share at any time prior to
November 1, 2007.

If L.A.M. sells any additional shares of common stock, or any securities
convertible into common stock at a price below the then applicable warrant
exercise price, the exercise price of the Series A warrants will be
lowered to the price at which the shares were sold or the lowest price at
which the securities are convertible, as the case may be.

-continued -

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

NOTES TO FINANCIAL STATEMENTS
- ------------------------------------------------------------------------------

Note J - Convertible Notes - continued
The Series B warrants allow the holders to purchase 1,312,500 shares of
L.A.M.'s common stock at a price of $0.80 per share at any time prior to
November 1, 2007. Within two days after the end of any period of ten
consecutive days that the closing bid price of L.A.M.'s common stock has
exceeded $1.20, L.A.M. has the right, upon 15 days advance written
notice to the holders of the Series B warrants, to force the holders to
exercise the unexercised portion of the Series B warrants.

The Series C warrants allow the holders to purchase 875,000 shares of
L.A.M.'s common stock at a price of $1.20 per share at any time prior to
November 1, 2007. Within two days after the end of any period of ten
consecutive days that the closing bid price of L.A.M.'s common stock has
exceeded $2.00, L.A.M. has the right, upon 15 days advance written
notice to the holders of the Series C warrants, to force the holders to
exercise the unexercised portion of the Series C warrants.

The Series D warrants allow the holders to purchase 656,250 shares of
L.A.M.'s common stock at a price of $1.60 per share at any time prior to
November 1, 2007. Within two days after the end of any period of ten
consecutive days that the closing bid price of L.A.M.'s common stock has
exceeded $2.50, L.A.M. has the right, upon 15 days advance written
notice to the holders of the Series D warrants, to force the holders to
exercise the unexercised portion of the Series D warrants.

L.A.M.'s right to force the warrant holders to exercise the Series, B, C
and D warrants is subject to a number of conditions, including the
following:

- there is in effect a registration statement which the holders
may use to sell the shares issuable upon the exercise of the warrants.

- L.A.M.'s common stock is listed for trading on the OTC
Bulletin Board

The conversion premium on the convertible notes at the date of issuance
and the number of common share equivalents outstanding are as follows:

-----------------------------------------------------------------------------

Number of Excess of Fair Value
Common Share Conversion of Common Stock Conversion
Equivalents Price Over Debentures Premium
-----------------------------------------------------------------------------

Issued in 2002 2,380,952 $ 0.294 $ 204,762 $204,762

-----------------------------------------------------------------------------

Converted in 2002 (98,640) $ 0.294

-----------------------------------------------

Outstanding at
December 31, 2002 2,282,312 $ 0.294
-----------------------------------------------

- continued -

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

NOTES TO FINANCIAL STATEMENTS
- ------------------------------------------------------------------------------

Note J - Convertible Notes - continued

The excess fair value of the common stock into which the notes can
convert at the conversion date over the proceeds is recorded as
conversion premium and is limited to the amount of the proceeds of the
debentures. Accordingly, 204,762 was recorded in 2002 as a charge to
conversion premium and a credit to additional paid-in capital in the
accompanying financial statements.

The Company issued convertible debentures during 1999 and 2000 having an
aggregate principal balance of $1,252,000 and $2,406,333, respectively.
These debentures were unsecured obligations of the Company that matured
over twelve months and bore interest at an annualized rate of 9.5%
payable at maturity. The debentures were convertible into common shares
of the Company at rates from $.50 to $3.00 per share (2 shares to .33
shares for each $1 of principal) at any time, at the option of the
holder. The common shares issued on conversion had a restriction as to
resale for a period of one year from the date that the original
debenture was issued. The Company could also redeem the debentures at
any time upon written notice and payment to the holder of all unpaid
principal and interest. The debentures were not subject to any sinking
fund requirements. Debentures in the amount of $2,060,083 were converted
during 2000 into 3,319,430 shares of the Company's common stock. On
August 9, 2001, the conversion terms for all debentures then outstanding
were revised. The number of shares to be issued upon conversion of the
notes, plus any accrued interest would be determined by dividing the
amount to be converted by $0.52. Note holders who agreed to convert on
these revised terms were also granted options to purchase shares of the
Company's common stock equal to 10% of the number of shares resulting
from conversion. The options are exercisable immediately at $0.58 per
share and expire in August 2002. During 2001, $1,489,750 of the
remaining debentures were converted to 853,167 shares with such
debenture holders receiving an additional 3,106,502 common shares and
options to purchase 424,493 shares of the Company's common stock. An
additional conversion premium of $1,057,844 was recognized in 2001
related to the revision of terms. During 2001, debentures with a
principal amount of $108,500 were repaid.

The excess fair value of the common stock into which the notes can
convert at the conversion date over the proceeds is recorded as
conversion premium and is limited to the amount of the proceeds of the
debentures. Accordingly, $2,395,093 and $1,252,000 was recorded in 2000
and 1999, respectively, as a charge to conversion premium and a credit
to additional paid-in capital in the accompanying financial statements.

Note K - Share and Option Grants
The Company has stock option plans under which employees, non-employee
directors, consultants and investors may be granted options to purchase
shares of the Company's common stock. Options have varying vesting and
expiration dates.

The Company has elected to follow APBO No. 25 and related
Interpretations in accounting for its stock-based compensation made to
its employees. APBO No. 25 requires no recognition of compensation
expense for most of the stock-based compensation arrangements provided
by the Company, namely, broad-based employee stock purchase plans and
option grants where the exercise price is equal to or less than the
market value at the date of grant. However, APBO No. 25 requires
recognition of compensation expense for variable award plans over the
vesting periods of such plans, based upon the then-current market values
of the underlying stock. In contrast, SFAS No. 123 requires recognition
of

-continued-

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

NOTES TO FINANCIAL STATEMENTS
- ------------------------------------------------------------------------------

Note K - Share and Option Grants - continued
compensation expense for grants of stock, stock options, and other
equity instruments, over the vesting periods of such grants, based on
the estimated grant-date fair values of those grants. Stock options and
awards made to investors and consultants are subject to the provisions
of SFAS No. 123.

Employees
During 2002, the Company granted stock options for 485,000 shares of
common stock to employees as compensation for services rendered at
exercise prices that were below the fair value of the common stock at
the date of grant. In accordance with APBO 25, the Company recognized
compensation expense of $71,934 as a charge against operations during
2002 for the difference between the fair value and the exercise price of
the common stock at the date of grant. Had the Company determined
compensation based on the fair value at the grant date for its stock
options under SFAS No. 123, the Company's net loss would have been
increased to the pro forma amounts indicated below:

For the year ended
December 31,
2002 2001
-----------------------

Net loss
As reported $6,299,217 $8,398,760
Pro forma $6,339,006 $8,398,760
Earnings per share
As reported $ 0.26 $ 0.53
Pro forma $ 0.26 $ 0.53

Consultants
During 2002 and 2001 the Company granted stock options for 1,517,000 and
1,710,000 shares, respectively, of common stock to consultants as
compensation for services rendered. In accordance with SFAS 123, the
Company recognized compensation expense during 2002 and 2001 of
$358,612, and $100,125, respectively, for the fair value of the options
at the date of grant using a Black Scholes option-pricing model.

Directors
During 2002 and 2001, the Company granted additional stock options for
2,000,000 and 4,275,000 shares, respectively, of common stock to
directors as compensation for services rendered. In accordance with SFAS
No. 123, the Company recognized compensation expense during 2002 and
2001 of $878,000 and $2,199,375, respectively, for the fair value of the
options at the date of the grant using a Black Scholes option-pricing
model.

Investors
During 2001, the Company granted stock options for 5,005,000 shares of
common stock to investors. In accordance with SFAS No. 123, the Company
recognized compensation expense during 2001 of $565,025 for the fair
value of the options at the date of grant using a Black Scholes
option-pricing model.

-continued-

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

NOTES TO FINANCIAL STATEMENTS
- ------------------------------------------------------------------------------

Note K - Share and Option Grants - continued The following assumptions were
used:

------------------------------------------------------------------------
December 31, 2002 2001
------------------------------------------------------------------------

Weighted Average Fair Value of $0.39 $ 0.26
Options
Weighted Average Exercise Price $0.67 $ 0.78
Expected Market Volatility 9.4% 7.0%
Risk Free Interest Rate 4.37% 4.76%
Expected Life (Years) 5.0 5.0
Expected Dividend Yield 0% 0%
------------------------------------------------------------------------

Stock option transactions for the two years ending December 31, 2002 are
summarized as follows:

------------------------------------------------------------------------
Weighted Average
Outstanding Exercise Price
------------------------------------------------------------------------

At December 31, 2000 2,394,466 $ 2.84
Granted 11,616,993 $ 0.73
Exercised (173,000) $ 0.65
Forfeited/Expired (992,966) $ 2.26
------------------------------------------------------------------------

At December 31, 2001 12,845,493 $ 0.80
Granted 4,002,000 $ 0.71
Exercised (5,083,975) $ 0.58
Forfeited/Expired (224,018) $ 1.72
------------------------------------------------------------------------

At December 31, 2002 11,539,500 $ 0.80
------------------------------------------------------------------------

The following table summarizes information about fixed stock options
outstanding at December 31, 2002:

----------------------------------------------------------------------
Options Outstanding Options Exerciseable
Weighted Weighted Weighted
Shares Average Average Shares Average
Range of Under Remaining Exercise Under Exercise
Exercise Option Life Price Option Price
Prices
----------------------------------------------------------------------

$ 0.58 - $1.00 10,789,500 5.02 $ 0.64 9,884,500 $ 0.62
$ 1.25 - $2.50 325,000 3.70 $ 2.19 325,000 $ 3.70
$ 2.75 - $4.00 400,000 2.32 $ 3.56 400,000 $ 2.32
$7.50 25,000 0.12 $ 7.50 25,000 $ 0.12
-------------------------------------------------------------------------

-continued-

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

NOTES TO FINANCIAL STATEMENTS
- ------------------------------------------------------------------------------

Note K - Share and Option Grants - continued
.
During 2002 and 2001, the Board of Directors authorized the repricing of
options to purchase shares of common stock at rates ranging from $0.58
and $2.00 and $0.58 to $0.90, respectively. Of the options repriced in
2002, 25,000 also had the expiration dated extended by 12 months. All
options repriced in 2001 maintained the same expiration terms.
Approximately 225,000 and 1,930,000 options, respectively were repriced
under this program, which accounted for approximately 2% and 15%,
respectively of options outstanding as of December 31, 2002 and 2001. In
accordance with SFAS 123, the Company recognized compensation expense
during 2002 and 2001 of $1,600 and $323,125, respectively for the fair
value of the options at the date they were repriced using a Black
Scholes option-pricing model.

During 2002 and 2001, the Board of Directors authorized the extension of
expiration dates of options to purchase shares of common stock. The
extensions were for periods ranging from 12 months to 36 months and 12
months to 24 months, respectively. Approximately 3,090,000 and 452,500
options, respectively were extended under this program, which accounted
for approximately 27% and 4%, respectively, of options outstanding as of
December 31, 2002 and 2001. In accordance with SFAS 123, the Company
recognized compensation expense during 2002 and 2001 of $70,980 and
$30,813, respectively for the fair value of the options at the date
their expiration date was extended using a Black Scholes option-pricing
model.

In 2002 and 2001, the Company granted awards of 2,346,500 and 1,213,900,
respectively, of common stock as compensation to outside consultants.
The Company has charged operations in 2002 and 2001 for the fair value
of the common stock awarded on the date of the grants in the amount of
$1,147,927 and $1,047,207, respectively.

Note L - Equity Line of Credit Agreement
On January 24, 2001, the Company entered into an equity line of credit
agreement with Hockbury Limited in order to establish a source of
funding for the development of the Company's technology. The equity line
of credit agreement established what is sometimes also referred to as an
equity drawdown facility. The Company issued 1,053,177 shares of common
stock and received $971,000 in net proceeds under the equity line of
credit agreement.

On July 22, 2002 the Company terminated the equity line of credit
agreement with Hockbury Limited. As consideration for the cancellation
of the agreement, the Company re-priced the warrants held by Hockbury
Limited to purchase 482,893 shares of common stock from a price of $4.56
per share to $1.35 per share. This re-pricing had no effect on
operations for the year ended December 31, 2002. The warrants may be
exercised at any time prior to January 24, 2004.

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

NOTES TO FINANCIAL STATEMENTS
- ------------------------------------------------------------------------------

Note M - Common Stock
The Company is authorized to issue 50,000,000 shares of common stock.
Holders of common stock are each entitled to cast one vote for each
share held of record on all matters presented to shareholders.
Cumulative voting is not allowed; hence, the holders of a majority of
the outstanding common stock can elect all directors.

Holders of common stock are entitled to receive such dividends as may be
declared by the Board of Directors out of funds legally available
therefore and, in the event of liquidation, to share pro rata in any
distribution of the Company's assets after payment of liabilities. The
Board of Directors is not obligated to declare a dividend and it is not
anticipated that dividends will be paid until the Company is profitable.

Holders of common stock do not have preemptive rights to subscribe to
additional shares if issued by the Company. There are no conversion,
redemption, sinking fund or similar provisions regarding the common
stock.

Note N - Lease Arrangements
The Company leases office space and a research facility under operating
leases which expire at various dates through 2004. The leases require
the payment of property and business taxes, insurance and maintenance
costs in addition to rental payments.

Future minimum payments are as follows:

2003 2004 2005 2006 2007 Total
------------------------------------------------------------------------
$ 76,636 $ 37,400 $-- $-- $-- $ 114,036
------------------------------------------------------------------------

Rent expense under operating leases was $63,811 and $66,965 for the
years ended December 31, 2002 and 2001, respectively.

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

NOTES TO FINANCIAL STATEMENTS
- ------------------------------------------------------------------------------

Note O - Contingencies
An investor relations firm formerly used by the Company
filed a claim against the Company with the American Arbitration
Association. The claim alleges that the Company failed to pay the
investor relations firm in accordance with the terms of an agreement
between the parties. On March 26, 2003 a hearing was held before an
arbitrator regarding this matter. At the hearing the investor
relations firm claimed damages from the Company in the amount of
approximately $600,000 as a result of the Company's breach of the
agreement. In contrast, the Company contends that the investor
relations firm did not provide the services required by the agreement
and as a result no additional amounts are due to the investor
relations firm. A decision by the arbitrator is expected by April 30,
2003.

While management is not able at the present time to determine the
outcome of these matters, based upon information currently available,
management presently believes that the probability is remote that its
resolution will have a material adverse effect on the Company's
financial position or results of operations.

Note P - Related Party Transactions
A director and shareholder of the Company is a partner in the law firm
that acts as counsel and patent attorneys to the Company. The Company
incurred legal fees and expenses to the law firm in the amount of
approximately $229,000 and $244,000 in 2002 and 2001, respectively.

Note Q - Concentrations
The Company recorded its first sales in August 2002. During 2002, the
largest customer accounted for 60% of net sales. As the Company has just
begun to sell its products, the Company does not believe that they are
dependent on the current customer base for future sales.

Note R - Subsequent Events
On February 4, 2003 the Company signed a binding Letter of Intent to
acquire selected assets of Actium Pharmaceuticals, Inc., a Delaware
corporation. Upon further due diligence, both parties agreed not to move
forward witht the transaction

On January 10, 2003, L.A.M. issued 750,000 options at an exercise price
of $0.58 to Mr. Drizen pursuant to an agreement signed on January 4,
2003. The 750,000 options have a vesting date of July 15, 2003 and
expire on July 15, 2008. These options will have no impact on the
statement of operations for the first quarter of 2003.

L.A.M. PHARMACEUTICAL, CORP.

(A DELAWARE CORPORATION)
Lewiston, New York

-------------------------------------
FINANCIAL REPORTS
AT
SEPTEMBER 30, 2003
-------------------------------------

L.A.M. PHARMACEUTICAL, CORP. (A DELAWARE CORPORATION) Lewiston, New York

TABLE OF CONTENTS
- --------------------------------------------------------------------------------

Balance Sheets at September 30, 2003 (Unaudited) and December 31, 2002 F-2

Statements of Changes in Stockholders' Equity (Deficit) for the
Nine Months Ended September 30, 2003 and 2002 (Unaudited) F-3

Statements of Operations for the Three Months Ended September 30, 2003
and 2002 (Unaudited) F-4

Statements of Operations for the Nine Months Ended September 30, 2003
and 2002 (Unaudited) F-5

Statements of Cash Flows for the Nine Months Ended September 30, 2003
and 2002 (Unaudited) F-6 to F-7

Notes to Financial Statements F-8 to F-9

The accompanying notes are an integral part of these financial statements.

F - 2
L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

BALANCE SHEETS
- --------------------------------------------------------------------------------
(Unaudited)
September 30, December 31,
2003 2002
- --------------------------------------------------------------------------------

ASSETS

Current Assets
Cash and Cash Equivalents $ 59,677 $ 210,214
Accounts Receivable 11,228 13,643
Inventory 499,828 550,085
Prepaid Expenses 76,757 5,812
Other Current Assets 19,224 874
- --------------------------------------------------------------------------------

Total Current Assets 666,714 780,628

Property and Equipment - Net of Accumulated 104,958 124,958
Depreciation

Other Assets
Patents and Trademarks - Net of Accumulated 605,245 546,631
Amortization
- --------------------------------------------------------------------------------

Total Assets $ 1,376,917 $ 1,452,217
- --------------------------------------------------------------------------------

LIABILITIES AND STOCKHOLDERS' DEFICIT

Current Liabilities
Accounts Payable and Accrued Expenses $ 933,355 $ 866,164
Accrued Arbitration Settlement 606,132 --
Convertible Notes 160,400 671,000
- --------------------------------------------------------------------------------

Total Current Liabilities 1,699,887 1,537,164

Other Liabilities
Due to Stockholders - due after one year 149,545 164,037
Deferred Royalty Revenue 207,360 207,360
- --------------------------------------------------------------------------------

Total Liabilities 2,056,792 1,908,561
- --------------------------------------------------------------------------------

Stockholders' Deficit
Common Stock - $.0001 Par; 50,000,000 Shares
Authorized; 33,463,318 and
27,511,412 Shares Issued and
Outstanding, Respectively 3,346 2,751
Additional Paid-In Capital 25,676,201 24,054,187
Accumulated Deficit (26,359,422) (24,513,282)
- --------------------------------------------------------------------------------

Total Stockholders' Deficit (679,875) (456,344)
- --------------------------------------------------------------------------------

Total Liabilities and Stockholders' Deficit $ 1,376,917 $ 1,452,217
- --------------------------------------------------------------------------------

The accompanying notes are an integral part of these financial statements.

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)

- ---------------------------------------------------------------------------------------------------------------------------------

Additional Loan Total
Number Common Paid-In Receivable - Accumulated Stockholders'
of Shares Stock Captial Director/Officer Deficit Equity (Deficit)
- ---------------------------------------------------------------------------------------------------------------------------------
Balance - December 31, 2001 19,784,520 $1,978 $ 17,964,009 $ (640,000) $(18,214,065) $ (888,078)

Capital Contribution - Interest Expense -- -- 16,906 -- -- 16,906
Stock Options Granted -
Compensation for Services Rendered -- -- 1,349,437 -- -- 1,349,437
Common Shares Issued -
Compensation for Services Rendered 1,496,500 150 913,102 -- -- 913,252
Stock Options Exercised 4,918,975 492 2,858,647 -- -- 2,859,139
Sale of Shares Under the Equity Line of
Credit Agreement 614,156 61 487,303 -- -- 487,364
Receivable on Option Exercise -- -- (396,000) -- -- (396,000)
Loan Repayments from Director/Officer -- -- -- 640,000 -- 640,000
Net Loss for the Period (Unaudited) -- -- -- -- (4,726,242) (4,726,242)
- --------------------------------------------------------------------------------------------------------------------------------
Balance - September 30, 2002 (Unaudited) 26,814,151 $2,681 $ 23,193,404 $ -- $(22,940,307) $ 255,778
- --------------------------------------------------------------------------------------------------------------------------------
Balance - December 31, 2002 27,511,412 $2,751 $ 24,054,187 $ -- $(24,513,282) $ (456,344)

Capital Contribution - Interest Expense -- -- 6,346 -- -- 6,346
Stock Options Granted -
Compensation for Services Rendered -- -- 27,148 -- -- 27,148
Common Shares Issued -
Compensation for Services Rendered 4,215,172 421 368,829 -- -- 369,250
Sale of Shares Under the Stock Subscriptions -- -- 684,265 -- -- 684,265
Receivable on Option Exercise -- -- 25,000 -- -- 25,000
Conversion of Convertible Notes 1,736,734 174 510,426 -- -- 510,600
Net Loss for the Period (Unaudited) -- -- -- -- (1,846,140) (1,846,140)
- -------------------------------------------------------------------------------------------------------------------------------
Balance - September 30, 2003 (Unaudited) 33,463,318 $3,346 $ 25,676,201 $ -- $(26,359,422) $ (679,875)
- -------------------------------------------------------------------------------------------------------------------------------

The accompanying notes are an integral part of these financial statements.

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

STATEMENTS OF OPERATIONS (UNAUDITED)
- --------------------------------------------------------------------------
Three Months Ended
September 30,
--------------------------------

2003 2002
- --------------------------------------------------------------------------

Revenues
Net Sales $ 26,163 $ 22,165
- --------------------------------------------------------------------------

Expenses
Cost of Sales 7,571 5,172
General and Administrative 179,276 570,902
Marketing and Business Development 67,080 360,611
Research and Development 26,760 114,146
- --------------------------------------------------------------------------
280,687 1,050,831
Financial Accounting Expenses
Not Requiring the Use of Cash During
the Period:
Depreciation and Amortization 17,717 15,916
Interest Expense 2,058 2,358
Share and Option Grants to Officers,
Directors, Investors and Consultants 139,666 407,917
- --------------------------------------------------------------------------

Total Expenses 440,128 1,477,022
- --------------------------------------------------------------------------

Loss Before Other Expenses (413,965) (1,454,857)
- --------------------------------------------------------------------------

Other Expenses
Provision for Arbitration Settlement 3,000 --
- --------------------------------------------------------------------------

Total Other Expenses 3,000 --
- --------------------------------------------------------------------------
$ (416,965) $ (1,454,857)
Net Loss for the Period
- --------------------------------------------------------------------------

Loss per Common Share - Basic and Diluted $ (0.01) $ (0.06)
- --------------------------------------------------------------------------

Weighted Average Number of Common Shares
Outstanding - Basic and Diluted 31,448,867 26,133,394
- --------------------------------------------------------------------------

The accompanying notes are an integral part of these financial statements.

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

STATEMENTS OF OPERATIONS (UNAUDITED)
- --------------------------------------------------------------------------
Nine Months Ended
September 30,
--------------------------------

2003 2002
- --------------------------------------------------------------------------

Revenues
Net Sales $ 79,784 $ 22,165
- --------------------------------------------------------------------------

Expenses
Cost of Sales 20,856 5,172
General and Administrative 506,951 1,154,563
Marketing and Business Development 330,123 748,557
Research and Development 147,142 432,683
- --------------------------------------------------------------------------
1,005,072 2,340,975
Financial Accounting Expenses
Not Requiring the Use of Cash During the
Period:
Depreciation and Amortization 51,616 45,220
Interest Expense 6,504 17,473
Share and Option Grants to Officers,
Directors, Investors and Consultants 256,600 2,344,739
- --------------------------------------------------------------------------

Total Expenses 1,319,792 4,748,407
- --------------------------------------------------------------------------

Loss Before Other Expenses (1,240,008) (4,726,242)
- --------------------------------------------------------------------------

Other Expenses
Provision for Arbitration Settlement 606,132 --
- --------------------------------------------------------------------------

Total Other Expenses 606,132 --
- --------------------------------------------------------------------------

Net Loss for the Period $ (1,846,140) $ (4,726,242)
- --------------------------------------------------------------------------

Loss per Common Share - Basic and Diluted $ (0.06) $ (0.20)
- --------------------------------------------------------------------------

Weighted Average Number of Common Shares
Outstanding - Basic and Diluted 30,107,786 23,913,887
- --------------------------------------------------------------------------

The accompanying notes are an integral part of these financial statements.

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

STATEMENTS OF CASH FLOWS (UNAUDITED)
- ---------------------------------------------------------------------------
Nine Months Ended
September 30,

2003 2002
- ---------------------------------------------------------------------------
Cash Flows from Operating Activities

Net Loss for the Period $ (1,846,140) $ (4,726,242)

Adjustments to Reconcile Net Loss for
the Period
to Net Cash Flows from Operating
Activities:
Depreciation and Amortization 51,616 45,220
Capital Contributions:
Deemed Interest Expense on
Loans from Stockholders 6,346 16,906
Share and Option Grants - Officers,
Directors, Investors, and
Consultants 396,398 2,107,682

Changes in Assets and Liabilities:
Accounts Receivable 2,415 (21,054)
Inventory 50,257 (334,842)
Prepaid Expenses (70,945) (57,223)
Other Current Assets (18,350) (1,000)
Accounts Payable and Accrued Expenses 276,141 396,662
Accrual for Arbitration Settlement 606,132 --
- ---------------------------------------------------------------------------
Net Cash Flows from Operating Activities (546,130) (2,573,891)
- ---------------------------------------------------------------------------

Cash Flows from Investing Activities
Purchases of Property and Equipment (1,495) (16,405)
Purchases of Patents and Trademarks -
Net (88,735) (139,914)
- ---------------------------------------------------------------------------
Net Cash Flows from Investing Activities (90,230) (156,319)
- ---------------------------------------------------------------------------

Cash Flows from Financing Activities
Proceeds from Exercise of Stock Options 25,000 1,357,303
Proceeds from the Sale of Shares Under
the
Stock Subscriptions 400,315 --
Proceeds from Sale of Shares Under the
Equity Line of Credit Agreement -- 487,364
Loan Receivable - Director/Officer -- 976,643
Advances from Stockholders 139,390 433
Repayments to Stockholders (78,882) --
- ---------------------------------------------------------------------------
Net Cash Flows from Financing Activities 485,823 2,821,743

Net Change in Cash and Cash Equivalents (150,537) 91,533
Cash and Cash Equivalents - Beginning
of Period 210,214 11,284
- ---------------------------------------------------------------------------
Cash and Cash Equivalents - End of $ 59,677 $ 102,817
Period
- ---------------------------------------------------------------------------

The accompanying notes are an integral part of these financial statements.

- -continued-

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

STATEMENTS OF CASH FLOWS (UNAUDITED) - continued
- ---------------------------------------------------------------------------

Nine Months Ended
September 30,
-----------------------------------

2003 2002
- ---------------------------------------------------------------------------
- ---------------------------------------------------------------------------
Non-Cash Investing and Financing
Activities
Exercise of Stock Options $ -- $ 857,450
Offsetting of Stockholders Receivable
and Payables $ -- $ 728,000
Debentures Converted to Common Stock $ 510,600 $ --
Stock Subscriptions - Offset against
due to stockholders $ 75,000 $ --

SUPPLEMENTAL DISCLOSURE

Interest Paid $ -- $ --
Income Taxes Paid $ -- $ --

The accompanying notes are an integral part of these financial statements.

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

NOTES TO FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------

Note A - Basis of Presentation
The condensed financial statements of L.A.M. Pharmaceutical, Corp. (the
"Company") included herein have been prepared by the Company, without
audit, pursuant to the rules and regulations of the Securities and
Exchange Commission (the "SEC"). Certain information and footnote
disclosures normally included in financial statements prepared in
conjunction with generally accepted accounting principles have been
condensed or omitted pursuant to such rules and regulations, although
the Company believes that the disclosures are adequate to make the
information presented not misleading. These condensed financial
statements should be read in conjunction with the Company's audited
financial statements and the notes thereto included elsewhere in this
prospectus.

The accompanying unaudited interim financial statements reflect all
adjustments of a normal and recurring nature, which are, in the opinion
of management, necessary to present fairly the financial position,
results of operations and cash flows of the Company for the interim
periods presented. The results of operations for these periods are not
necessarily comparable to, or indicative of, results of any other
interim period or for the fiscal year as a whole. Factors that affect
the comparability of financial data from year to year and for comparable
interim periods include non-recurring expenses associated with market
launch of new products, costs incurred to raise capital, acquisitions of
patents and trademarks, and stock options and awards.

Reclassifications
Certain amounts in the prior year financial statements have been
reclassified to conform with the current year presentation.

Note B - Accounting Policies
Revenue Recognition
The Company recognizes revenue when it is realized or realizable and
earned. The Company considers revenue realized or realizable when the
product has been shipped to the customer, the sales price is fixed or
determinable and collectibility is reasonably assured. The Company
reduces revenue for estimated customer returns.

Method of Accounting
The Company maintains its books and prepares its financial statements on
the accrual basis of accounting.

Note C - Inventory

Inventory at period end consisted of the following:
------------------------------------------------------------------------
September 30, December 31,
2003 2002
------------------------------------------------------------------------
IPM Wound Gel(TM) $ 489,203 $539,460
Raw Materials 10,625 10,625
------------------------------------------------------------------------

Inventory $ 499,828 $550,085
------------------------------------------------------------------------

Note D - Share and Option Grants The Company has stock option plans under
which employees, non-employee directors, consultants and investors may
be granted options to purchase shares of the Company's common stock.
Options have varying vesting and expiration dates.

The Company applies Accounting Principles Board Opinion No. 25,
"Accounting for Stock Issued to Employees", and related interpretations
in accounting for its employee stock option plans. Accordingly,

-continued-

L.A.M. PHARMACEUTICAL, CORP.
(A DELAWARE CORPORATION)
Lewiston, New York

NOTES TO FINANCIAL STATEMENTS
- --------------------------------------------------------------------------------

Note D - Share and Option Grants - continued

no compensation expense has been recognized for its employee stock
option plans. During the first quarter of fiscal 2003, the Company
adopted the disclosure provisions of SFAS No. 148, "Accounting for
Stock-Based Compensation - Transition and Disclosure".

The following table illustrates the effect on net earnings and earnings
per share had the Company adopted the fair value based method of
accounting for stock-based employee compensation for all periods
presented:

For the three months For the nine months
ended September 30, ended
September 30,
2003 2002 2003 2002
----------------------------------------------
Net loss
As reported $ 416,965 $1,454,857 $1,846,140 $4,726,242
Pro forma $ 424,791 $1,454,857 $1,857,484 $4,726,242
Earnings per share
As reported $0.01 $0.06 $ 0.06 $ 0.20
Pro forma $0.01 $0.06 $ 0.06 $ 0.20

Note E - Common Stock
During the three months ended September 30, 2003 the Company sold units
of Company's common stock in which each unit consists of 1000 shares of
the Company's common stock plus 750 warrants. Each warrant will entitle
the holder to purchase one of the Company's common stock as follows:

o One third of warrants may be exercised at any time prior to
February 28, 2005 at a price of $0.30 per share
o One third of warrants may be exercised at any time prior to
August 31, 2005 at a price of $0.30 per share
o One third of warrants may be exercised at any time prior to
February 28, 2006 at a price of $0.50 per share

Between July 1, 2003 and October 14, 2003 the Company sold 7,341,828
shares of its common stock, plus warrants for the purchase of an
additional 5,247,750 shares for proceeds and debt reduction amounting to
a total of $958,000. A total of 4,974,828 shares, plus warrants for the
purchase of 3,472,000 shares were sold to thirty-nine investors for
$673,960 in cash. An additional 2,367,000 shares, plus warrants for the
purchase of 1,775,250 shares, were sold to five persons in payment of
$284,040 owed by the Company to these persons.

Note F - Commitments & Contingencies
In May 2003, the Company learned that the American Arbitration
Association awarded damages in the amount of approximately $600,000 to
an investor relations firm formerly used by the Company due to an
alleged breach of contract. The arbitration decision did not specify a
due date for the award. The investor relations company has contacted the
Company indicating that they would like to reach a negotiated settlement
that would not result in any damage to the Company's prospects. The
Company believes that the settlement may be made through the issuance of
shares rather than a cash payment or possibly a reduced amount of cash
and or shares. In addition, payment may be delayed to a future date or
may be structured to occur over time. At present, the outcome of this
settlement is not determinable and accordingly the Company has accrued
the entire amount plus interest, at a rate of 2% per annum, as an
expense and liability in the financial statements for the period ended
September 30, 2003.

No dealer salesman or other person has been authorized to give any information
or to make any representations, other than those contained in this prospectus.
Any information or representation not contained in this prospectus must not be
relied upon as having been authorized by L.A.M. This prospectus does not
constitute an offer to sell, or a solicitation of an offer to buy, the
securities offered hereby in any state or other jurisdiction to any person to
whom it is unlawful to make such offer or solicitation. Neither the delivery of
this prospectus nor any sale made hereunder shall, under any circumstances,
create an implication that there has been no change in the affairs of L.A.M.
since the date of this prospectus.

TABLE OF CONTENTS

Page

Prospectus Summary....................................
Risk Factors..........................................
Comparative Share Data................................
Market for Common Stock...............................
Management's Discussion and Analysis and Plan of Operation..................
Business..............................................
Management............................................
Principal Shareholders................................
Selling Shareholders..................................
Description of Securities.............................
Experts...............................................
Indemnification.......................................
Additional Information................................
Financial Statements..................................

Common stock

L.A.M. PHARMACEUTICAL CORP.

PROSPECTUS